Activatable IL-18 polypeptides

Act-IL-18 polypeptides address the issue of systemic off-target effects in cytokine therapies by selectively activating at tumor sites, enhancing local IL-18 activity and minimizing autoimmune risks, thus improving cancer treatment efficacy.

CN119072488APending Publication Date: 2024-12-03BRIGHT PEAK THERAPEUTICS AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380035667.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-23
Filing Date
2023-02-23
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing cytokine therapies for cancer treatment, such as IL-18 administration, result in systemic distribution leading to off-target effects and autoimmune diseases due to indiscriminate activation of IL-18 receptors, limiting their therapeutic efficacy.

Method used

Development of an activatable IL-18 (Act-IL-18) polypeptide with an artificial end portion that is inactivated systemically but activated selectively at the tumor microenvironment, minimizing off-target effects by preferential cleavage at specific sites, such as protease-sensitive or redox-sensitive cleavage sites, to enhance local IL-18 activity.

Benefits of technology

Act-IL-18 polypeptides minimize systemic side effects while maintaining targeted immune response enhancement, increasing local IL-18 concentration at tumor sites, thereby reducing off-target activation and enhancing therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072488A_ABST
    Figure CN119072488A_ABST
Patent Text Reader

Abstract

The present disclosure relates to activatable IL-18 polypeptides, compositions comprising activatable IL-18 polypeptides, methods of making activatable IL-18 polypeptides, and methods of treating diseases using activatable IL-18 polypeptides. In one aspect, the disclosure relates to cancer treatment using activatable IL-18 polypeptides.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 313,210, filed on February 23, 2022, which is incorporated herein by reference in its entirety. Background Art

[0003] Immunotherapy uses the subject's immune system to help treat a disease. Immunotherapy can be designed to activate or suppress the immune system, depending on the nature of the disease being treated. The goal of immunotherapy for treating cancer is to stimulate the immune system so that it recognizes and destroys tumors or other cancerous tissue. One way to activate the immune system in a subject to attack cancer cells is cytokine therapy. Cytokines are proteins produced in the body that are important in cell signaling and regulating the immune system. Some cytokine therapies use these properties of cytokines to enhance the subject's immune system to kill cancer cells. Summary of the invention

[0004] Provided herein is an activatable IL-18 (Act-IL-18) polypeptide that is activated in response to certain conditions or stimuli present in a target area of ​​a subject after administration. In some cases, Act-IL-18 is administered in an inactivated form, and then releases the active form of the IL-18 polypeptide upon contact with the condition or stimulus. In some cases, this allows the IL-18 polypeptide to preferentially regulate the immune response in the target area of ​​the subject (such as a cancer or tumor microenvironment). In some cases, Act-IL-18 exhibits fewer side effects associated with systemic administration and distribution of the corresponding active IL-18 polypeptide. In some embodiments, Act-IL-18 of the present disclosure comprises an artificial end portion, such as a peptide, connected to the end (e.g., N-terminus or C-terminus) of the IL-18 polypeptide, which is used to inactivate the IL-18 polypeptide. In some embodiments, the artificial end portion is cleaved under one or more conditions associated with the desired target area (e.g., tumor microenvironment), thereby releasing the active IL-18 polypeptide.

[0005] Figure 1A Depicted are exemplary mechanisms of action of activatable IL-18 polypeptides as provided herein, wherein the IL-18 polypeptide comprises an artificial terminal moiety that renders Act-IL-18 inactive, which upon cleavage of the artificial terminal moiety, produces an active form of the IL-18 polypeptide. Figure 1BA similar concept is illustrated, where an artificial terminal portion is attached to the N-terminus of an IL-18 polypeptide. The depicted artificial terminal portion comprises a connecting peptide B, which connects a protease cleavage site having a specific cleavage site to the N-terminus of the IL-18 polypeptide. The artificial terminal portion also comprises a connecting peptide A, which connects the protease cleavage site to a blocking portion (labeled "mask" in the figure). After cleavage at the specific cleavage site, the mask and connecting peptide A are released from the IL-18 polypeptide, but the connecting peptide B remains. This results in the formation of an active form of the IL-18 polypeptide. Figure 1C and Figure 1B Similar, but the artificial terminal moiety is attached to the C-terminus of the IL-18 polypeptide.

[0006] In some embodiments, Act-IL-18 comprises an artificial terminal portion comprising a blocking group connected to an IL-18 polypeptide. In some embodiments, the position of the blocking portion is such that the cleavage of the artificial terminal portion releases the blocking portion from the IL-18 polypeptide, thereby allowing the IL-18 polypeptide to interact with the receptor (or to a higher degree with the receptor). In some embodiments, the blocking portion includes an IL-18 propeptide (e.g., the N-terminal portion of immature IL-18, which is endogenously cleaved by caspase to produce mature IL-18). In some embodiments, the IL-18 propeptide is connected to a specific cleavage site of the IL-18 polypeptide, which is cleaved by a protease other than caspase (e.g., a protease upregulated in a tumor or tumor microenvironment). In some embodiments, the IL-18 propeptide is connected to the N-terminus of the IL-18 polypeptide. In some embodiments, the blocking moiety includes a domain of an IL-18 receptor subunit, such as the D3 domain of the IL-18 receptor α subunit (for a description of the IL-18 receptor domain architecture, see, e.g., Tsutsumi et al., Nature Communications 5:5340 | DOI: 10.1038 / ncomms6340, published Dec. 15, 2014).

[0007] In one aspect, the present invention provides an activatable interleukin 18 (Act-IL-18) polypeptide, comprising: an artificial end portion linked to an interleukin 18 (IL-18) polypeptide, wherein the artificial end portion comprises a specific cleavage site, and wherein cleavage at the specific cleavage site converts the Act-IL-18 to an active form of the IL-18 polypeptide. In some embodiments, when the artificial end portion is intact, the Act-IL-18 is inactive.

[0008] In some embodiments, the specific cleavage site is preferentially cleaved at or near a target tissue in a subject. In some embodiments, the specific cleavage site is preferentially cleaved in or near a tumor microenvironment.

[0009] In some embodiments, the specific cleavage site is specifically cleaved by a protease. In some embodiments, relative to non-tumor tissue, the protease is present in a higher concentration in the tumor microenvironment and / or exhibits higher proteolytic activity. In some embodiments, the protease is selected from: kallikrein, thrombin, chymase, carboxypeptidase A, elastase, protease 3 (PR-3), granzyme M, calpain, matrix metalloproteinase (MMP), disintegrin and metalloproteinase (ADAM), fibroblast activation protein α (FAP), plasminogen activator, cathepsin, caspase, tryptase and tumor cell surface protease. In some embodiments, the artificial end portion comprises a peptide having a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to the peptide sequence listed in Table 2A. In some embodiments, the artificial end portion comprises a peptide having a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a peptide sequence listed in Table 2B.

[0010] In some embodiments, the specific cleavage site is a redox-sensitive cleavage site. In some embodiments, the redox-sensitive cleavage site is preferentially cleaved in a reducing environment. In some embodiments, the specific cleavage site is a pH-sensitive cleavage site. In some embodiments, the pH-sensitive cleavage site is preferentially cleaved at a pH below 7.3, below 7.2, below 7.1, or below 7.0.

[0011] In some embodiments, the cleavage removes the entire artificial terminal portion from the IL-18 polypeptide. In some embodiments, the cleavage results in a portion of the artificial moiety remaining attached to the IL-18 polypeptide.

[0012] In some embodiments, the artificial end portion is a peptide. In some embodiments, the cleavage of the artificial end portion at the specific cleavage site leaves no amino acid residues of the peptide attached to the IL-18 polypeptide. In some embodiments, the cleavage of the artificial end portion at the specific cleavage site leaves at least 1 amino acid residue of the peptide attached to the IL-18 polypeptide. In some embodiments, the cleavage of the artificial end portion at the specific cleavage site leaves 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid residues of the peptide attached to the IL-18 polypeptide. In some embodiments, the peptide comprises multiple specific cleavage sites. In some embodiments, the peptide comprises 2, 3 or 4 specific cleavage sites. In some embodiments, the length of the peptide is 2 to 35 amino acid residues. In some embodiments, the length of the peptide is 8, 9 or 10 amino acid residues.

[0013] In some embodiments, the artificial terminal moiety is attached to the N-terminus or the C-terminus of the IL-18 polypeptide.

[0014] In some embodiments, the artificial end portion is connected to the N-terminus of the IL-18 polypeptide. In some embodiments, the artificial end portion comprises a blocking portion. In some embodiments, the blocking portion is positioned so that the cleavage at the specific cleavage site releases the blocking portion from the Act-IL-18 polypeptide. In some embodiments, the blocking portion includes an IL-18 propeptide or a portion thereof, or a variant thereof. In some embodiments, the IL-18 propeptide is a human IL-18 propeptide or a variant thereof. In some embodiments, the IL-18 propeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence shown in SEQ ID NO: 89. In some embodiments, the artificial end portion comprises a connecting peptide between the specific cleavage site and the blocking portion.

[0015] In some embodiments, the artificial end portion is connected to the C-terminus of the IL-18 polypeptide. In some embodiments, wherein the blocking portion is positioned so that the cleavage at the specific cleavage site releases the blocking portion from the Act-IL-18 polypeptide. In some embodiments, the blocking portion includes a domain of an IL-18 receptor subunit or a portion thereof, or a derivative thereof. In some embodiments, the domain of the IL-18 receptor subunit includes the D3 domain of the IL-18 receptor α subunit, or a variant thereof. In some embodiments, the blocking portion comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence shown in SEQ ID NO: 93. In some embodiments, the artificial end portion comprises a connecting peptide between the specific cleavage site and the blocking portion. In some embodiments, the Act-IL-18 polypeptide comprises a connecting peptide between the IL-18 polypeptide and the specific cleavage site.

[0016] In some embodiments, the active form of the IL-18 polypeptide exhibits reduced binding to IL-18 binding protein (IL-18BP) compared to WT IL-18. In some embodiments, the active form of the IL-18 polypeptide exhibits enhanced binding to IL-18R or the ability to activate IL-18R. In some embodiments, the active form of the IL-18 polypeptide exhibits up to a 100-fold reduction in binding to IL-18R or the ability to activate IL-18R relative to WT IL-18.

[0017] In some embodiments, the IL-18 polypeptide comprises one or more modifications to the sequence set forth in SEQ ID NO: 1. In some embodiments, the IL-18 polypeptide comprises an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO: 1. In some embodiments, the IL-18 polypeptide comprises at least one substitution at the following residues: Y1, F2, E6, C38, K53, D54, S55, T63, C76, E85, M86, T95, D98, or C127, or any combination thereof. In some embodiments, the IL-18 polypeptide comprises Y01G, F02A, E06K, V11I, C38S, C38A, K53A, D54A, S55A, T63A, C76S, C76A, E85C, M86C, T95C, D98C, C127S or C127A amino acid substitutions, or any combination thereof. In some embodiments, the IL-18 polypeptide comprises E06K and K53A amino acid substitutions. In some embodiments, the IL-18 polypeptide comprises a T63A amino acid substitution. In some embodiments, the IL-18 polypeptide comprises a V11I amino acid substitution. In some embodiments, the IL-18 polypeptide comprises a substitution at 1, 2, 3 or 4 residues selected from C38, C76, C98 and C127. In some embodiments, the IL-18 polypeptide comprises an amino acid sequence as set forth in any one of SEQ ID Nos: 2-67. In some embodiments, the IL-18 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 30. In some embodiments, the IL-18 polypeptide comprises the amino acid sequence shown in any one of SEQ ID NOs: 79-83.

[0018] In some embodiments, the Act IL-18 polypeptide exhibits a half-maximal effective concentration (EC) of IL-18 receptor signaling activity that is at least 1,000-fold higher, 2,000-fold higher, 5,000-fold higher, 10,000-fold higher, 15,000-fold higher, or 20,000-fold higher than the activated form of the IL-18 polypeptide. 50 In some embodiments, the Act IL-18 polypeptide exhibits a half-maximal effective concentration (EC) of IL-18 receptor signaling activity that is about 10 to about 100 times higher than the activated form of the IL-18 polypeptide. 50 In some embodiments, the activated form of the IL-18 polypeptide exhibits a half maximal effective concentration (EC) of IL-18 receptor signaling activity that is within about 10-fold of that of the IL-18 polypeptide. 50In some embodiments, the Act-IL-18 polypeptide exhibits a half-maximal effective concentration (EC) of IL-18 receptor signaling activity that is at least 10-fold greater than that of WT IL-18. 50 ).

[0019] In some embodiments, the IL-18 polypeptide is synthetic.

[0020] In some embodiments, a polymer is linked to a residue of the IL-18 polypeptide.

[0021] On the other hand is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a pharmaceutically effective amount of an Act-IL-18 polypeptide or pharmaceutical composition provided herein. In some embodiments, the cancer is a solid cancer. In some embodiments, the solid cancer is adrenal cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, carcinoid, cervical cancer, colorectal cancer, esophageal cancer, eye cancer, gallbladder cancer, gastrointestinal stromal tumor, germ cell cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, nasal and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, neuroendocrine cancer, oral cancer, oropharyngeal cancer, ovarian cancer, pancreatic cancer, pediatric cancer, penile cancer, pituitary cancer, prostate cancer, skin cancer, soft tissue cancer, spinal cord cancer, gastric cancer, testicular cancer, thymus cancer, thyroid cancer, ureteral cancer, uterine cancer, vaginal cancer or vulvar cancer. In some embodiments, the solid cancer is a carcinoma or sarcoma. In some embodiments, the cancer is a blood cancer. In some embodiments, the hematological cancer is leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, AIDS-related lymphoma, multiple myeloma, plasmacytoma, post-transplant lymphoproliferative disorder, or Waldenstrom macroglobulinemia. In some embodiments, the method comprises reconstituting a lyophilized form of the Act-IL-18 polypeptide or the pharmaceutical composition.

[0022] Another aspect provides a method of preparing an Act-IL-18 polypeptide provided herein, the method comprising synthesizing two or more fragments of the Act-IL-18 polypeptide, concatenating the fragments, and folding the concatenated fragments.

[0023] Other aspects and advantages of the present disclosure will become apparent to those skilled in the art from the following detailed description, in which only illustrative embodiments of the present disclosure are shown and described. As will be appreciated, the present disclosure is capable of other and different embodiments, and its several details are capable of modification in various obvious aspects, all without departing from the present disclosure. Therefore, the drawings and description are to be regarded as illustrative in nature, rather than restrictive.

[0024] Incorporated by Reference

[0025] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. If a publication or patent or patent application incorporated by reference contradicts the disclosure contained in the specification, the specification is intended to supersede and / or take precedence over any such contradictory material. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] The novel features of the present disclosure are particularly set forth in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by referring to the following detailed description and the accompanying drawings, which set forth illustrative embodiments in which the principles of the present disclosure are utilized, wherein:

[0027] Figure 1A A schematic representation of an exemplary activation mechanism of Act-IL-18 as provided herein is shown.

[0028] Figure 1B A schematic representation of an exemplary activation mechanism of an Act-IL-18 polypeptide having a blocking moiety ("mask" in the figure) attached to the N-terminus of the IL-18 polypeptide is shown.

[0029] Figure 1C A schematic representation of an exemplary activation mechanism of an Act-IL-18 polypeptide having a blocking moiety ("mask" in the figure) attached to the C-terminus of the IL-18 polypeptide is shown.

[0030] Figure 2 The diagram shows the mechanism of action of IL-18 on IFNγ and IL-18BP production, and the inhibitory activity of IL-18BP on IL-18.

[0031] Figure 3 The conjugation of dibenzocyclooctyne (DBCO) polyethylene glycol (PEG) to an azide-containing IL-18 polypeptide is shown.

[0032] Figure 4 The diagram shows the binding of a polymer-containing IL-18 polypeptide to IL-18Rα.

[0033] Figure 5A The IFNγ inducing ability of the IL-18 polypeptides of the present disclosure is shown compared to the wild-type IL-18 polypeptide.

[0034] Figure 5B IL-18BP inhibition is shown for IL-18 polypeptides of the present disclosure compared to wild-type IL-18 polypeptide.

[0035] Figure 6A schematic diagram showing the coupling of a bifunctional probe to an IL-18 polypeptide provided herein.

[0036] Figure 7 A schematic diagram of the coupling of a poly(ethylene glycol) moiety to an IL-18 polypeptide activated with a bifunctional probe is shown.

[0037] Figure 8 Shown is a conditionally activatable IL-18 with a terminal protease recognition sequence linked to a blocking moiety and an orthogonal conjugation handle.

[0038] Fig. 9 Conditionally activatable IL-18 polypeptides with N-terminal proteases are shown.

[0039] Fig. 10A A conditionally activatable IL-18 with a C-terminal protease recognition sequence as well as a blocking moiety and an orthogonal conjugation handle is shown.

[0040] Fig. 10B A conditionally activatable IL-18 with a C-terminal protease recognition sequence and an orthogonal conjugation handle is shown.

[0041] Fig.11 An illustrative example of a conditionally activatable, conjugatable IL-18 polypeptide is shown, in which the three N-terminal residues are replaced with a protease recognition sequence and a blocking moiety. Following proteolytic processing in the tumor microenvironment (TME), a functional IL-18 mutant protein is revealed.

[0042] Fig.12 An illustrative example of a conditionally activatable, conjugatable IL-18 polypeptide is shown in which the three C-terminal residues are replaced with a protease recognition sequence and a blocking moiety. Following proteolytic processing in the TME, a functional IL-18 mutant protein is revealed.

[0043] Fig.13 An illustrative example of a conditionally activatable IL-18 polypeptide is shown, in which the three N-terminal residues are replaced by a protease recognition sequence and a conjugation handle. After proteolytic processing in the TME, a free functional IL-18 mutant protein is revealed.

[0044] Fig.14A Shown is an SDS-PAGE gel of the activatable IL-18 polypeptides provided herein before and after MMP treatment.

[0045] Fig. 14B Shown is an SDS-PAGE gel of the activatable IL-18 polypeptides provided herein before and after MMP treatment.

[0046] Fig. 14CShown is an SDS-PAGE gel showing the activatable IL-18 polypeptides provided herein after MMP treatment and resin purification. FT indicates flow-through and E indicates eluate.

[0047] Fig.15A Shown are dose response curves for IL-18 receptor activation for the activatable IL-18 polypeptides provided herein.

[0048] Fig. 15B Shown are dose response curves for IL-18 receptor activation for the activatable IL-18 polypeptides provided herein.

[0049] Fig.16A Shown are the sequences and peptide maps of the activatable IL-18 polypeptides provided herein.

[0050] Fig. 16B Shown are the sequences and peptide maps of the activatable IL-18 polypeptides provided herein. DETAILED DESCRIPTION

[0051] The immune response to tumors is primarily a function of type 1 T helper (Th1) lymphocytes. The Th1 response includes the secretion of cytokines IL-2, IL-12, IL-18, IFNγ, and the production of specific cytotoxic T lymphocytes that recognize specific tumor antigens. The Th1 response is an important weapon for the host to defend against many microorganisms. However, the Th1 response is also associated with autoimmune diseases and organ transplant rejection.

[0052] Interleukin 18 (IL-18) is a proinflammatory cytokine that initiates or promotes biological activities of host defense and inflammation following infection or injury. IL-18 has been implicated in autoimmune diseases, myocardial function, emphysema, metabolic syndrome, psoriasis, inflammatory bowel disease, hemophagocytic syndrome, macrophage activation syndrome, sepsis, and acute kidney injury. In some disease models, IL-18 plays a protective role.

[0053] IL-18 also plays an important role in the production of IFNγ by T cells and natural killer cells. IFNγ is a Th1 cytokine produced primarily by T cells, NK cells, and macrophages, and is essential for innate and adaptive immunity against viral, some bacterial, and protozoan infections. IFNγ is also an important activating factor for macrophages and an inducer of the expression of class II major histocompatibility complex (MHC) molecules.

[0054] IL-18 forms a signaling complex by binding to the IL-18 α chain (IL-18Rα), which is the ligand-binding chain of mature IL-18. However, IL-18 has a low binding affinity to IL-18Rα. In cells expressing the co-receptor IL-18 receptor β chain (IL-18Rβ), a high-affinity heterodimeric complex is formed, which then activates cell signaling.

[0055] The activity of IL-18 is counteracted by the presence of a high-affinity, naturally occurring IL-18 binding protein (IL-18BP). IL-18BP binds to IL-18 and neutralizes the biological activity of IL-18. IL-18Rα on the cell surface competes with IL-18BP for the binding of IL-18. Increased disease severity may be associated with an imbalance between IL-18 and IL-18BP, resulting in elevated levels of free IL-18 in the circulation. Figure 2 Diagram showing the mechanism of action of IL-18, IFNγ production, IL-18BP production, and IL-18BP inhibition of IL-18 activity. IL-18 induces IFNγ production, which in turn induces IL-18BP production. IL-18BP then competes with IL-18Rα to inhibit IL-18 activity. This feedback loop of IL-18BP production after stimulation of IFNγ production has limited the effectiveness of IL-18 as a previously attempted therapeutic modality.

[0056] In order to counteract this inactivation, the IL-18 variants that are reduced in combination with IL-18BP are currently being studied. Non-limiting examples of such variants include variants with amino acid substitutions that inhibit binding to IL-18BP, such as variants found in PCT Publication Nos. WO2019051015A1 and WO2002101049A2, each of which is hereby incorporated by reference, as if it were set forth herein in its entirety. However, high levels of IL-18 in serum are likely to produce harmful off-target effects by indiscriminately activating the IL-18 receptors in non-target tissues and cells. These off-target effects include lymphopenia, hyperglycemia, anemia, neutropenia, hypoalbuminemia, liver damage, elevated liver enzymes, lymphopenia, increased lymphocyte activation, and increased serum concentrations of creatinine, IFN-γ, and granulocyte macrophage colony stimulating factor. Importantly, high levels of circulating free IL-18 that are not bound by neutralizing IL-18BP are associated with the development of potentially life-threatening systemic autoinflammatory / autoimmune diseases such as adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA), and are also associated with the most serious complication of these diseases, macrophage activation syndrome (MAS).

[0057] In order to prevent immune-related adverse events or minimize these off-target and systemic effects, an activatable form of interleukin 18 (Act-IL-18) is provided herein. In some cases, Act-IL-18 is activated by a disease (such as cancer or tumor microenvironment) associated with a target tissue. In some cases, Act-IL-18 is preferentially activated in or near the target tissue, thereby causing an increase in the local concentration of active IL-18 relative to non-target tissues. This in turn minimizes the off-target effects of IL-18, but allows IL-18 to still regulate the local immune response in the target tissue.

[0058] In some embodiments, it has been observed herein that a small portion attached to the end of an IL-18 polypeptide (e.g., a short peptide sequence or a small linker attached to the N-terminus or C-terminus of an IL-18 polypeptide, particularly to the N-terminus) can functionally inhibit the activity of an IL-18 polypeptide. Although it has been previously observed that another 36 amino acid segment at the N-terminus of endogenous IL-18 is cleaved by caspases when initially expressed, it was previously unclear whether other portions (e.g., shorter peptide sequences) attached to the end of mature IL-18 could inhibit IL-18 activity. In fact, others have observed that IL-18 fusion proteins comprising a 36 amino acid precursor peptide segment retain IL-18 receptor signaling activity (see, e.g., PCT Publication No. WO2005014642A2, which is hereby incorporated by reference as if set forth herein in its entirety).

[0059] In some embodiments, the Act-IL-18 polypeptides provided herein utilize a blocking portion attached to an IL-18 polypeptide via a cleavable group in order to inhibit and / or reduce the activity of the IL-18 polypeptide. Such blocking portions may include an IL-18 propeptide attached via a novel cleavable group (e.g., not an endogenous cleavable group of full-length, immature IL-18), or the D3 domain of the α subunit of the IL-18 receptor. In such cases, cleavage of the specific cleavage group of the Act-IL-18 polypeptide releases the blocking portion, thereby generating an activated form of the IL-18 polypeptide.

[0060] On the one hand, provided herein is an Act-IL-18 comprising an artificial end portion, which inactivates an IL-18 polypeptide at an off-target position, but is cleaved to produce an active IL-18 polypeptide. In some embodiments, the artificial end portion conditionally interferes with the binding between the IL-18 receptor (IL-18Rαβ) and Act-IL-18. In some embodiments, the conversion of the artificial end portion by conditions in or near the target tissue (e.g., disease tissue, such as a tumor microenvironment) weakens the receptor binding interference provided by the artificial end portion. In some embodiments, the artificial end portion interferes with the binding between the IL-18 polypeptide and the IL-18 receptor in non-target tissues. In some embodiments, the conversion of the artificial end portion (e.g., the cleavage of the artificial end portion or other changes in the artificial end portion, such as oxidation / reduction or conformational changes) results in the converted Act-IL-18 having an increased IL-18 receptor binding affinity and / or activation relative to Act-IL-18 that has not yet been converted. In some embodiments, target tissue-specific conversion and activation of Act-IL-18 provides active IL-18 for treating tumors, while minimizing active IL-18 in non-target tissues and cells. In some embodiments, the active form of the IL-18 polypeptide exhibits a reduced ability to bind to and / or be neutralized by IL-18BP.

[0061] The following description and examples illustrate the embodiments of the present disclosure in detail. It should be understood that the present disclosure is not limited to the specific embodiments described herein, and therefore can be varied. Those skilled in the art will recognize that the present disclosure has many variations and modifications, which are all encompassed within the scope of the present disclosure.

[0062] Although various features of the disclosure may be described in the context of a single embodiment, these features may also be provided separately or in any suitable combination. Conversely, although the disclosure may be described herein in the context of separate embodiments for clarity, the disclosure may also be implemented in a single embodiment.

[0063] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0064] I. Definitions

[0065] All terms are intended to be understood in the manner that one skilled in the art would understand. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0066] The following definitions supplement those in the art and are for the present application and should not be attributed to any related or unrelated circumstances, such as any commonly owned patents or applications. Although any methods and materials similar or equivalent to those described herein can be used to practice testing of the present disclosure, preferred methods and materials are described herein. Accordingly, the terms used herein are only used for the purpose of describing specific embodiments and are not intended to be limiting.

[0067] The terms used herein are for the purpose of describing a particular situation only and are not intended to be limiting. In this application, unless otherwise specifically stated, the use of the singular includes the plural. As used herein, the singular forms "a", "an", and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0068] In this application, the use of "or" means "and / or" unless otherwise stated. As used herein, the terms "and / or" and "any combination thereof" and their grammatical equivalents may be used interchangeably. These terms may indicate that any combination is specifically contemplated. For purposes of illustration only, the following phrases "A, B, and / or C" or "A, B, C, or any combination thereof" may mean "A alone; B alone; C alone; A and B; B and C; A and C; and A, B, C". The term "or" may be used in conjunction or separately, unless the context clearly indicates separate use.

[0069] The term "about" or "approximately" can mean within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean within 1 or more than 1 standard deviation, according to the practice in the art. Alternatively, "about" can mean a range of up to 20%, up to 15%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or biological processes, the term can mean within an order of magnitude, within 5-fold, or within 2-fold of a value. When describing a particular value in the application and claims, unless otherwise indicated, it should be assumed that the term "about" means within an acceptable error range for the particular value.

[0070] As used in this specification and claims, the words "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have" and "has"), "including" (and any form of including, such as "include" and "include"), or "containing" (and any form of "containing", such as "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. It is contemplated that any embodiment discussed in this specification can be implemented with reference to any method or composition of the present disclosure, and vice versa. In addition, the compositions of the present disclosure can be used to implement the methods of the present disclosure.

[0071] References in the specification to "some embodiments," "embodiments," "one embodiment," or "other embodiments" mean that a particular feature, structure, or characteristic described in conjunction with the embodiments is included in at least some embodiments of the present disclosure, but not necessarily in all embodiments. To facilitate understanding of the present disclosure, some terms and expressions are defined as follows.

[0072] As used herein, "α-keto amino acid" or the term "α-keto" before the name of an amino acid refers to an amino acid or amino acid derivative having a keto functional group located between the carbon bearing the amino group and the carboxylic acid of the amino acid. The α-keto amino acid of the present disclosure has a structure as shown in the following formula:

[0073]

[0074] Wherein R is the side chain of any natural or non-natural amino acid. According to standard amino acid nomenclature, the R functional group can be in the L or D direction. In a preferred embodiment, the α-keto amino acid is in the L direction. When the wording "α-keto" is used before the name of a conventional natural amino acid (e.g., α-ketoleucine, α-ketophenylalanine, etc.) or before the name of a common non-natural amino acid (e.g., α-ketonorleucine, α-ketoO-methyl-homoserine, etc.), it is intended that the α-keto amino acid mentioned matches the above formula with the side chain of the amino acid mentioned. When an α-keto amino acid residue is shown in a peptide or polypeptide sequence herein, it is intended that the protected version of the relevant α-keto amino acid is also covered (e.g., for a sequence terminated with a C-terminal α-keto amino acid, the terminal carboxylic acid group can be appropriately capped with a protecting group (such as a tert-butyl group), or the keto group can be appropriately capped with an acetal protecting group). Other protecting groups covered are well known in the art.

[0075] Binding affinity refers to the strength of the binding interaction between a single molecule and its ligand / binding partner. A higher binding affinity means a higher bond strength than a lower binding affinity. In some cases, binding affinity is measured by the dissociation constant (K) between two molecules of interest. D ) to measure. When comparing K D When K is a value of , binding interactions with lower values ​​have higher binding affinity than those with higher values. For protein-ligand interactions, K D Calculated according to the following formula:

[0076]

[0077] where [L] is the concentration of ligand, [P] is the concentration of protein, and [LP] is the concentration of ligand / protein complex.

[0078] This article mentions certain amino acid sequences (for example, peptide sequences) with certain sequence identity percentages with a reference sequence, or mentions the residue at a position corresponding to the position of the reference sequence. Sequence identity is measured by the protein-protein BLAST algorithm using the following parameters of the matrix BLOSUM62: gap cost presence: 11, extension: 1 and composition adjustment conditional composition score matrix adjustment (Compositional Adjustments Conditional Compositional Score Matrix Adjustment). This comparison algorithm is also used to assess whether a residue is in a "corresponding" position by analyzing the comparison of the two sequences compared.

[0079] Unless otherwise indicated, for sequence identity purposes, particularly for chemically synthesized polypeptides, it is expected that "protected" versions of amino acids (e.g., amino acids containing a chemical protecting group attached to an amino acid functional group, particularly the side chain of an amino acid, but also at another point of the amino acid) are considered the same as "unprotected" versions. It is also expected that such protected versions are also encompassed in the SEQ ID NOs provided herein. Non-limiting examples of protecting groups that may be encompassed include fluorenylmethyloxycarbonyl (Fmoc), trityl (trityl or trt), tert-butyloxycarbonyl (Boc), 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf), acetamidomethyl (Acm), tert-butyl (tBu or OtBu), 2,2-dimethyl-1-(4-methoxyphenyl)propane-1,3-diol ketal or acetal, and 2,2-dimethyl-1-(2-nitrophenyl)propane-1,3-diol ketal or acetal. Other protecting groups well known in the art are also contemplated. Similarly, for sequence identity purposes, modified forms of natural amino acids are also intended to be considered natural forms of amino acids. For example, amino acids containing side chain heteroatoms that can be covalently modified (e.g., to add a conjugation handle, optionally through a linker), such as lysine, glutamine, glutamic acid, asparagine, aspartic acid, cysteine, or tyrosine that have been covalently modified will be considered basic amino acids (see, e.g., Structure 2 below, which will be considered lysine for sequence identity and SEQ ID purposes). Similarly, amino acids containing another group added to the C-terminus or N-terminus will be considered basic amino acids.

[0080] The amino acid or amino acid sequence that appears in the "upstream" of another reference amino acid sequence is mentioned herein. The term "upstream" in this context means that the indicated amino acid or amino acid sequence is attached to the N-terminal residue of the amino acid sequence mentioned (for example, the methionine residue located upstream of the sequence "SDGTK" will have a "MSDGTK" sequence). In some cases, the residue numbering of the "upstream" amino acid or amino acid sequence uses a negative numbering system (for example, with reference to the position of -1, -2 or -3 positions relative to the reference sequence). When using this numbering system, the -1 position corresponds to the amino acid attached to the N-terminal of the reference sequence, and the -2 position corresponds to the amino acid attached to the N-terminal of the -1 position, and so on. For example, the AM sequence located upstream of the reference sequence SDGTK will produce a complete AMSDGTK sequence, wherein M is located at the -1 position relative to the reference sequence, and A is located at the -2 position.

[0081] The term "pharmaceutically acceptable" means approved or approvable by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, including humans.

[0082] A "pharmaceutically acceptable excipient, carrier, or diluent" refers to an excipient, carrier, or diluent that can be administered to a subject with an agent without destroying its pharmacological activity and that is nontoxic when administered in doses sufficient to deliver therapeutic amounts of the agent.

[0083] "Pharmaceutically acceptable salts" suitable for the present disclosure may be acid or base salts generally considered in the art to be suitable for use in contact with human or animal tissues without excessive toxicity, irritation, allergic reaction or other problems or complications. Such salts include basic residues such as mineral and organic acid salts of amines, and acidic residues such as alkali or organic salts of carboxylic acids. Specific pharmaceutical salts include, but are not limited to, salts of the following acids: such as hydrochloric acid, phosphoric acid, hydrobromic acid, malic acid, glycolic acid, fumaric acid, sulfuric acid, aminosulfonic acid, para-aminobenzenesulfonic acid, formic acid, toluenesulfonic acid, methanesulfonic acid, benzenesulfonic acid, ethanedisulfonic acid, 2-hydroxyethylsulfonic acid, nitric acid, benzoic acid, 2-acetoxybenzoic acid, citric acid, tartaric acid, lactic acid, stearic acid, salicylic acid, glutamic acid, ascorbic acid, pamoic acid, succinic acid, fumaric acid, maleic acid, propionic acid, hydroxymaleic acid, hydroiodic acid, phenylacetic acid, alkanoic acids such as acetic acid, HOOC-(CH2) n -COOH, wherein n is 0, 2, 3, 4 or 4 etc. Similarly, pharmaceutically acceptable cations include but are not limited to sodium, potassium, calcium, aluminum, lithium and ammonium. Those of ordinary skill in the art will recognize from the disclosure and knowledge in the art that other pharmaceutically acceptable salts include those listed in Remington's Pharmaceutical Sciences, 17th edition, Mack Publishing Company, Easton, PA, page 1418 (1985). In general, pharmaceutically acceptable acid salts or base salts can be synthesized by any conventional chemical method from a parent compound containing an alkaline or acidic part. In brief, such salts can be prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of an appropriate base or acid in an appropriate solvent.

[0084] The ranges provided herein are understood to be shorthand for all values ​​within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or subrange from the group consisting of: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50, and all intermediate decimal values ​​between the above integers, such as, for example, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, and 1.9. With respect to sub-ranges, "nested sub-ranges" extending from either end of the range are specifically contemplated. For example, nested sub-ranges of the exemplary range of 1 to 50 may include 1 to 10, 1 to 20, 1 to 30, and 1 to 40 in one direction, or 50 to 40, 50 to 30, 50 to 20, and 50 to 10 in the other direction.

[0085] The term "subject" refers to an animal that is the object of treatment, observation or experiment. By way of example only, a subject includes, but is not limited to, a mammal, including, but not limited to, a human or a non-human mammal, such as a non-human primate, bovine, equine, canine, ovine or feline.

[0086] The term "optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0087] As used herein, the term "number average molecular weight" (Mn) means the statistical average molecular weight of all individual units in a sample and is defined by formula (1):

[0088]

[0089] Among them, M i is the molecular weight of the unit, and N i is the number of units of that molecular weight.

[0090] As used herein, the term "weight average molecular weight" (Mw) means the number defined by formula (2):

[0091]

[0092] Among them, M i is the molecular weight of the unit, and N i is the number of units of that molecular weight.

[0093] As used herein, "peak molecular weight" (Mp) means the molecular weight of the highest peak in a given analytical method (eg, mass spectrometry, size exclusion chromatography, dynamic light scattering, analytical centrifugation, etc.).

[0094] As used herein, "conjugation handle" refers to a reactive group that can form a bond when contacting a complementary reactive group. In some cases, the conjugation handle is preferably not substantially reactive with other molecules that do not contain the expected complementary reactive group. Non-limiting examples of conjugation handles, their respective complementary conjugation handles, and corresponding reaction products can be found in the following table. Although the table header places certain reactive groups under the heading "conjugation handle" or "complementary conjugation handle", it is intended that any reference to the conjugation handle may alternatively cover the complementary conjugation handles listed in the table (for example, trans-cyclooctene can be a conjugation handle, in which case tetrazine will be a complementary conjugation handle). In some cases, amine conjugation handles and conjugation handles complementary to amines are less preferred for use in biological systems because amines are ubiquitous in biological systems and the possibility of off-target conjugation increases.

[0095] Table with conjugated handle

[0096]

[0097] Throughout this application, prefixes are used before the term "conjugation handle" to indicate the functional group to which the conjugation handle is attached. For example, a "protein conjugation handle" is a conjugation handle that is attached to a protein (directly or through a linker), an "antibody conjugation handle" is a conjugation handle that is attached to an antibody (directly or through a linker), and a "PEG conjugation handle" is a conjugation handle that is attached to a PEG group (e.g., directly or through a linker).

[0098] II. IL-18 Activatable Polypeptides

[0099] The present disclosure relates to activatable IL-18 (Act-IL-18) polypeptides that can be used as therapeutic agents. The activatable IL-18 polypeptides provided herein can be used as immunotherapy or as part of other immunotherapy regimens.

[0100] In one aspect, the present disclosure relates to an artificial moiety attached to an IL-18 polypeptide. The artificial moiety may comprise peptides, amino acids, and other groups, such as polymers or spaces for attaching the artificial moiety to the IL-18 polypeptide. The artificial moiety comprises a cleavable group that, when cleaved, releases all or part of the terminal moiety. After cleavage, Act-IL-18 is converted to an active form of the IL-18 polypeptide that is capable of exerting IL-18 activity.

[0101] In one aspect, provided herein are Act-IL-18 polypeptides comprising an artificial end portion attached to an IL-18 polypeptide. In some embodiments, the artificial end portion inhibits the Act-IL-18 polypeptide from interacting with an IL-18 receptor and / or signaling through an IL-18 receptor. In some embodiments, the artificial end portion is capable of undergoing a change in response to a condition or stimulus, thereby resulting in conversion of the Act-IL-18 polypeptide to an active IL-18 polypeptide. In some embodiments, the change is cleavage of at least a portion of the artificial end portion from the IL-18 polypeptide.

[0102] On the one hand, Act-IL-18 of the present disclosure is activated in or near the target tissue of the subject. In some embodiments, Act-IL-18 is preferentially activated in or near the target tissue of the subject (e.g., activated at a higher rate in or near the target tissue compared to other tissues). In some embodiments, Act-IL-18 is preferentially activated at or near the target tissue of the subject, so that compared to non-target tissues, the area at or near the target tissue contains at least 2 times, at least 4 times, at least 8 times, at least 10 times, at least 15 times, at least 20 times, at least 50 times, at least 100 times, at least 200 times, at least 500 times or at least 1000 times the concentration of the active form of IL-18 polypeptide. In some embodiments, the concentration of comparison is the peak concentration of the active form of IL-18 polypeptide after the administration of Act-IL-18. In some embodiments, Act-IL-18 is preferentially activated in or near the diseased tissue of the subject. In some embodiments, the Act-IL-18 polypeptide is preferentially activated in or near the cancerous tissue of the subject. In some embodiments, the Act-IL-18 polypeptide is preferentially activated in or near a tumor microenvironment. In some embodiments, Act-IL-18 is preferentially activated in a tumor microenvironment compared to non-tumor tissue.

[0103] In one aspect, provided herein is an activatable interleukin 18 (Act-IL-18) polypeptide, comprising: an artificial end portion linked to an interleukin 18 (IL-18) polypeptide, wherein the artificial end portion comprises a specific cleavage site, and wherein cleavage at the specific cleavage site converts the Act-IL-18 to an active form of the IL-18 polypeptide.

[0104] Artificial part

[0105] In one aspect, provided herein is an artificial portion connected to an IL-18 polypeptide. As provided herein, an artificial portion is used to modulate the activity of an IL-18 polypeptide when connected in an intact form. In some embodiments, cleavage of the artificial portion is used to activate the IL-18 polypeptide (e.g., allowing the IL-18 polypeptide to signal through IL-18Rαβ). The artificial portion provided herein can be connected to any residue. In some embodiments, the artificial portion is an artificial terminal portion (e.g., connected to the terminal residue of the IL-18 polypeptide).

[0106] In some embodiments, the artificial moiety may have additional functional groups attached (e.g., in addition to attachment to the IL-18 polypeptide, the artificial moiety is also attached to another group, such as another polypeptide (e.g., an antibody, a pseudoreceptor, another cytokine), a half-life extending polymer (e.g., poly(ethylene glycol) (PEG)), or another desired functional group. In some embodiments, cleavage of the artificial moiety also serves to cleave the additional group from the IL-18 polypeptide.

[0107] Artificial end part

[0108] On the one hand, the Act-IL-18 polypeptide provided herein comprises an artificial terminal portion. In some embodiments, the artificial terminal portion is a functional group covalently linked to the IL-18 polypeptide, such as a peptide, a small molecule or other group. In some embodiments, the artificial terminal portion is a peptide. When the artificial terminal portion is a peptide, in some cases, it is also referred to as an "artificial terminal peptide" herein. The artificial terminal portion is a group that is not naturally linked to the end of the WT IL-18 polypeptide, such as a 36 amino acid propeptide of the natural precursor of WT IL-18 directly linked to WT IL-18. When the IL-18 polypeptide is a variant IL-18 polypeptide (e.g., with at least one amino acid substitution relative to WT IL-18), the artificial terminal portion can be a natural propeptide. In some embodiments, the artificial terminal peptide is engineered to have the characteristics provided herein. In some embodiments, the artificial terminal portion is fused to the IL-18 polypeptide (e.g., as a fusion protein). In some embodiments, the artificial terminal portion is chemically linked to the IL-18 polypeptide, or is incorporated into the IL-18 polypeptide by synthetic means (e.g., during the synthesis of the IL-18 polypeptide).

[0109] In some embodiments, the artificial end portion provided herein inhibits at least one activity associated with an IL-18 polypeptide, such as the ability to bind to an IL-18 receptor or to signal through an IL-18 receptor (IL-18Rαβ) (e.g., inducing IFNγ production in immune cells). In some embodiments, when the artificial end portion is intact, the Act-IL-18 polypeptide is in an inactive state (e.g., lacks the ability to bind to IL-18Rαβ or to signal through IL-18Rαβ or has a significantly reduced ability to do so).

[0110] In some embodiments, the presence of the entire artificial end portion on the IL-18 polypeptide causes the Act-IL-18 polypeptide to exhibit a binding affinity for IL-18Rαβ or IL-18R subunit that is at least 10-fold lower, at least 100-fold lower, at least 200-fold lower, at least 500-fold lower, or at least 1000-fold lower than WT IL-18. In some embodiments, the presence of the entire artificial end portion on the IL-18 polypeptide causes the Act-IL-18 polypeptide to exhibit a binding affinity for IL-18Rαβ or IL-18R subunit that is at least 10-fold lower, at least 100-fold lower, at least 200-fold lower, at least 500-fold lower, or at least 1000-fold lower than IL-18 polypeptide without the artificial end portion.

[0111] In some embodiments, the presence of the complete artificial end portion on the IL-18 polypeptide causes the Act-IL-18 polypeptide to exhibit an ability to induce IFNg production in a cell (e.g., an immune cell, such as a NK cell) that is at least 10-fold lower, at least 100-fold lower, at least 200-fold lower, at least 500-fold lower, or at least 1000-fold lower than WT IL-18. In some embodiments, the presence of the complete artificial end portion on the IL-18 polypeptide causes the Act-IL-18 polypeptide to exhibit an ability to induce IFNγ production in a cell (e.g., an immune cell, such as a NK cell) that is at least 10-fold lower, at least 100-fold lower, at least 200-fold lower, at least 500-fold lower, or at least 1000-fold lower than an IL-18 polypeptide without the artificial end portion.

[0112] In some embodiments, the artificial end portion comprises a specific cleavage site. In some embodiments, the specific cleavage site is a site that is easy to cut under certain specified or known conditions. Non-limiting examples of specific cleavage sites include protease cleavage sites, sites that are easy to cut within certain pH ranges (e.g., acid-labile bonds), sites that are easy to cut via oxidation or reduction (e.g., disulfide bonds), photocleavable joints, etc.

[0113] In some embodiments, the specific cleavage site is selected so that it is preferentially cleaved at the designated target tissue of the subject (e.g., cleaved at a faster rate or cleaved with greater abundance). In some embodiments, the specific cleavage site is preferentially located at or near the target tissue of the subject, so that the cleavage rate of the specific cleavage site is at least 2 times, at least 4 times, at least 8 times, at least 10 times, at least 15 times, at least 20 times, at least 50 times, at least 100 times, at least 200 times, at least 500 times, or at least 1000 times higher than the cleavage rate of the specific cleavage site at a different tissue. In some embodiments, the target tissue is a diseased tissue of the subject. In some embodiments, the target tissue is a cancerous tissue of the subject. In some embodiments, the target tissue is a tumor microenvironment. In some embodiments, the target tissue is a tumor.

[0114] In some embodiments, the specific cleavage site is positioned such that all or only a portion of the artificial end portion is removed from the IL-18 polypeptide after cleavage. In some embodiments, no artificial end portion is present on the IL-18 polypeptide after cleavage (e.g., only residues corresponding to residues in SEQ ID NO: 1 are present after cleavage). In some embodiments, a portion of the artificial end portion remains attached to the IL-18 polypeptide after cleavage.

[0115] The artificial terminal portion can be connected to the N-terminal residue or the C-terminal residue of the IL-18 polypeptide. In some embodiments, the artificial terminal portion is connected to the N-terminal residue. In some embodiments, the artificial terminal portion is connected to the N-terminal amine of the IL-18 polypeptide. In some embodiments, the artificial terminal portion is connected to the C-terminal residue. In some embodiments, the artificial terminal portion is connected to the C-terminal carboxyl of the IL-18 polypeptide. In some embodiments, the N-terminal residue is the residue closest to residue position 1 of SEQ ID NO: 1 present on the IL-18 polypeptide as provided herein (e.g., the first residue of SEQ ID NO: 1 that is not truncated). In some embodiments, the N-terminal residue of the IL-18 polypeptide is the residue at the position corresponding to position 1 in SEQ ID NO: 1. In some embodiments, the N-terminal residue of the IL-18 polypeptide is Y1. In some embodiments, the N-terminal residue of the IL-18 polypeptide is Y1G. In some embodiments, the C-terminal residue is the residue at position 157 of SEQ ID NO: 1. In some embodiments, the C-terminal residue is D157.

[0116] In some embodiments, the terminal residue of the IL-18 polypeptide is substituted so that the artificial terminal portion is positioned so that the entire artificial terminal portion is cleaved from the IL-18 polypeptide. For example, if it is intended to introduce a cleavage site at the position corresponding to residue 1 of SEQ ID NO: 1, the protease cleavage sequence P1-P2-P3-P' may be selected.1- P' 2- P'3 (wherein the cleavage site is between P3 and P'1), and residues 1, 2, and 3 of SEQ ID NO: 1 may be substituted with P'1, P'2, and P'3, respectively, and P1-P2-P3- is appended thereto. In this case, the artificial end portion would be considered to comprise P1-P2-P3-, wherein P'1, P'2, and P'3 are part of the IL-18 polypeptide (the substituted residues).

[0117] Examples of artificial terminal moieties and their mechanisms of action are shown in Figures 8 to 13 middle. Figure 8 An artificial terminal peptide attached to the terminal residue of an IL-18 polypeptide is depicted. Also attached to the artificial portion is a blocking portion, which facilitates maintaining the IL-18 polypeptide in an inactive state. When the artificial terminal portion is cleaved (e.g., by a tumor microenvironment protease), the entire artificial terminal portion is cleaved (revealing the terminal residue of the IL-18 polypeptide, as is the blocking portion). The IL-18 in this example has a conjugation handle attached to other locations of the IL-18 polypeptide, which can be used to attach additional groups (e.g., a half-life extending polymer or an additional polypeptide), and can be attached before or after cleavage of the artificial terminal portion.

[0118] Fig. 9 An Act-IL-18 construct similar to the above is shown, but lacking the blocking moiety. In some cases, the presence of only a short peptide at the N-terminus is sufficient to modulate the activity of the IL-18 polypeptide, and activity can be restored after cleavage.

[0119] Fig. 10A Shown with Figure 8 The construct shown is similar to the Act-IL-18 construct, but with an artificial terminal moiety attached to the C-terminus.

[0120] Fig. 10B Shown with Fig. 9 The construct shown is similar to the Act-IL-18 construct, but with an artificial terminal moiety attached to the C-terminus.

[0121] Fig.11 Depicted with Figure 8 The construct shown is a construct similar to that shown above, but residues 1, 2 and 3 of the IL-18 polypeptide are substituted such that the artificial terminal portion is completely cleaved (residues 1, 2 and 3, although substituted, still correspond to positions 1, 2 and 3 of SEQ ID NO: 1). Fig.12 and Fig.11 Similar, but with the artificial end portion located at the C-terminus. Fig.11As an alternative to replacing residues 1, 2, and 3 of IL-18 as depicted, a cleavable peptide can be selected such that native residues 1, 2, and 3 (e.g., Y, F, and G, respectively) of the IL-18 polypeptide, or a subset of the native residues, form part of a cleavage recognition site for a relevant protease, such that the entire artificial terminal portion is cleaved, thereby leaving an unmodified N-terminus of the IL-18 polypeptide after cleavage. For example, a -PLG- sequence can be appended to the N-terminal Y of the IL-18 polypeptide to allow complete cleavage of the artificial terminal portion by a matrix metalloprotease. This approach can also be employed at the C-terminus of the IL-18 polypeptide.

[0122] Fig.13 Depicted is an Act-IL-18 polypeptide comprising an artificial end portion to which a conjugation handle is attached, such that cleavage of the artificial end portion also cleaves the conjugation handle (or anything attached to the conjugation handle) from the IL-18 polypeptide. As a non-limiting example, such a construct can be used to conjugate an antibody to an IL-18 polypeptide. Such a construct can be used to deliver an IL-18 polypeptide tissue-specifically, followed by activation of the IL-18 polypeptide at a desired site by cleavage at the target tissue.

[0123] Peptide artificial end portion

[0124] In some embodiments, the artificial terminal moiety comprises a peptide (also known as an "artificial terminal peptide"). In some embodiments, the artificial terminal moiety consists of a peptide.

[0125] In some embodiments, cleavage at the specific cleavage site leaves no amino acid residue attached to the IL-18 polypeptide. In some embodiments, cleavage at the specific cleavage site leaves at least 1 amino acid residue attached to the IL-18 polypeptide. In some embodiments, cleavage at the specific cleavage site leaves at most 1, 2, 3, 4, or 5 amino acid residues attached to the IL-18 polypeptide. In some embodiments, cleavage at the specific cleavage site leaves 1, 2, 3, 4, or 5 amino acid residues attached to the IL-18 polypeptide. In some embodiments, cleavage at the cleavage site leaves 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid residues attached to the IL-18 polypeptide.

[0126] In some embodiments, Act-IL-18 may optionally contain a tag for expressing and / or purifying recombinant Act-IL-18 as provided herein. The tag may be located upstream of the N-terminal artificial terminal peptide or downstream of the C-terminal artificial terminal peptide. The tag may be removed (e.g., enzymatically) before final formulation and / or administration to a subject. Exemplary tags include HIS6 (H HHHHH, SEQ ID NO: 84), Strep tag (WSHPQFEK (SEQ ID NO: 85) or AWAHPQPGG (SEQ ID NO: 86), or chitin binding tag (TTNP GVSAWQVNTAYTAGQLVTYNGKTYKCLQPHTSLAGWEPSNVPAL WQLQ, SEQ ID NO: 87).

[0127] Protease-cleavable artificial terminus

[0128] In some embodiments, the artificial end portion can be cleaved by a protease (e.g., the artificial end portion comprises a cleavable peptide). In some embodiments, the artificial end portion contains a cleavage site that can be specifically cleaved by one or more proteases. In some embodiments, the artificial end portion contains a cleavage site that can be cleaved at one or more protease preferred sites. In some embodiments, the specific cleavage site is a protease cleavage site.

[0129] In some embodiments, the protease is present in a higher concentration at or near a target tissue of a subject and / or exhibits higher proteolytic activity. In some embodiments, the target tissue is a disease tissue. In some embodiments, the target tissue is cancer. In some embodiments, the target tissue is a tumor microenvironment.

[0130] In some embodiments, relative to non-tumor tissue, the protease is present at or near the tumor microenvironment at a higher concentration and / or exhibits higher proteolytic activity. In some embodiments, relative to non-tumor tissue, the protease is present at or near the tumor microenvironment at a higher concentration. In some embodiments, relative to non-tumor tissue, the protease exhibits higher proteolytic activity at or near the tumor microenvironment. In some embodiments, the protease is selected from: kallikrein, thrombin, chymase, carboxypeptidase A, elastase, proteinase 3 (PR-3), granzyme M, calpain, matrix metalloproteinase (MMP), disintegrin and metalloproteinase (ADAM), fibroblast activation protein alpha (FAP), plasminogen activator, cathepsin, caspase, tryptase and tumor cell surface protease. In some embodiments, the cleavable peptide is cleaved by a protease selected from the group consisting of kallikrein, thrombin, chymase, carboxypeptidase A, elastase, proteinase 3 (PR-3), granzyme M, calpain, matrix metalloproteinase (MMP), a disintegrin and metalloproteinase (ADAM), fibroblast activation protein alpha (FAP), plasminogen activator, cathepsin, caspase, tryptase, proteinase, and tumor cell surface protease, or any combination thereof. In some embodiments, the protease is selected from the group consisting of kallikrein, thrombin, chymase, carboxypeptidase A, elastase, proteinase 3 (PR-3), granzyme M, urokinase plasminogen activator (uPA), calpain, matrix metalloproteinase (MMP), a disintegrin and metalloproteinase (ADAM), fibroblast activation protein alpha (FAP), proteinase, plasminogen activator, cathepsin, caspase, tryptase, and tumor cell surface protease. In some embodiments, the cleavable peptide is cleaved by a protease selected from the group consisting of kallikrein, thrombin, chymase, carboxypeptidase A, elastase, proteinase 3 (PR-3), urokinase plasminogen activator (uPA), granzyme M, calpain, matrix metalloproteinase (MMP), disintegrin and metalloproteinase (ADAM), fibroblast activation protein alpha (FAP), proteinase, plasminogen activator, cathepsin, caspase, tryptase, proteinase and tumor cell surface protease, or any combination thereof. In some embodiments, the protease is urokinase plasminogen activator (uPA) or proteinase. In some embodiments, the cleavable peptide can be cleaved by urokinase plasminogen activator (uPA) or proteinase. In some embodiments, the protease is a protease selected from Table 1 or Table 2A. In some embodiments, the protease is a protease selected from Table 2B.

[0131] Table 1 - Tissue / tumor specific proteases

[0132]

[0133]

[0134]

[0135] In some embodiments, the protease cleavage site is included in the recognition sequence identified by the protease. In some embodiments, the recognition sequence is a natural peptide sequence that has been incorporated into an artificial end portion. In some embodiments, the recognition sequence is a synthetic (for example, artificial, designed or engineered) sequence. In some embodiments, the recognition sequence comprises an amino acid sequence with at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or 100% identity with the sequence listed in Table 2A.

[0136] Table 2A - Protease-specific peptide recognition sequences

[0137]

[0138]

[0139] In some embodiments, the recognition sequence comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to a sequence listed in Table 2B.

[0140] Table 2B - Additional specific peptide recognition sequences

[0141]

[0142]

[0143]

[0144] In some embodiments, cleavage of the specific cleavage site leaves no amino acid residue attached to the IL-18 polypeptide. In such cases, the protease recognition sequence can be selected so that various parts of the IL-18 polypeptide constitute part of the recognition sequence, or are compatible with it. For example, in some embodiments, the sequence PLG is appended to the N-terminus of the IL-18 polypeptide (e.g., residue 1 of SEQ ID NO: 1), which results in a specific cleavage site located between the G of PLG and the N-terminus of the IL-18 polypeptide, thereby producing a "scarless" activated IL-18 polypeptide after cleavage.

[0145] In some embodiments, a portion of the protease recognition sequence that defines the specific cleavage site will be included in the sequence of the IL-18 polypeptide (e.g., a portion of the protease recognition sequence will be included at a position corresponding to a position in SEQ ID NO: 1). In some embodiments, the portion of the protease recognition sequence included in the IL-18 polypeptide sequence will be substituted relative to the sequence set forth in SEQ ID NO: 1. For example, in some embodiments, the last three amino acids of SEQ ID NO: 1 are substituted with -PLG to form a portion of the protease recognition site with the artificial terminal portion.

[0146] In some embodiments, cleavage at the specific cleavage site leaves at least 1 amino acid residue attached to the IL-18 polypeptide. In some embodiments, cleavage at the specific cleavage site leaves at most 1, 2, 3, 4, or 5 amino acid residues attached to the IL-18 polypeptide. In some embodiments, cleavage at the specific cleavage site leaves 1, 2, 3, 4, or 5 amino acid residues attached to the IL-18 polypeptide. In some embodiments, cleavage at the cleavage site leaves 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid residues attached to the IL-18 polypeptide. In some embodiments, cleavage at the specific cleavage site leaves at most 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues attached to the IL-18 polypeptide.

[0147] Other exemplary cleavable peptide sequences that can be incorporated into Act-IL-18 polypeptides as provided herein can be found in any of the following: U.S. Patent Publication Nos.: US2010 / 0189651, US2016 / 0289324, US2018 / 0125988, US2019 / 0153115, US2020 / 0385469, US2021 / 0260163, US2022 / 0048949, US2022 / 0267400, US2021 / 0115102, US2022 / 0002370, US2021 / 0163562, US20200392235, US 2021 / 0139553, US2021 / 0317177, US2020 / 0283489, US2021 / 0002343, US2021 / 0292421, US2021 / 0284728, US2021 / 0269530, US2022 / 0054544, US2021 / 0355219, US2022 / 0073613, US2021 / 0047406, and / or Patent Cooperation Treaty Publication Numbers: WO2021 / 202675, WO2021 / 062406, WO2021 / 142471, WO2021 / 216468, WO2021 / 119516, WO2021 / 253360, W 02021 / 146455, WO2021 / 202678, WO2021 / 202673, WO2021 / 189139, WO2020 / 232303, WO2022 / 115865, WO2021 / 202678, and / or Chen et al., J Bio Chem, 277, V6 P4485-4491 (2002).

[0148] Redox-cleavable artificial end moiety

[0149] In some cases, different tissues of a subject may exhibit different redox potentials depending on tissue activity. For example, tumors and tumor microenvironments are associated with significantly greater reduction potentials than other healthy tissues. Thus, in some embodiments, the artificial end portions provided herein utilize this property to allow for preferential cleavage and activation of IL-18 polypeptides at tissue sites.

[0150] In some embodiments, the artificial end portion can be cut by reduction or oxidation reaction. In some embodiments, the artificial end portion contains a cleavage site that can be specifically cut by reduction or oxidation reaction. In some embodiments, the artificial end portion contains a cleavage site that can be cut at a preferred site of reduction or oxidation reaction. In some embodiments, the specific cleavage site is a redox sensitive cleavage site.

[0151] In some embodiments, the redox-sensitive cleavage site is preferentially cleaved at or near the target tissue of the subject, such that the cleavage rate of the specific cleavage site is at least 2 times, at least 4 times, at least 8 times, at least 10 times, at least 15 times, at least 20 times, at least 50 times, at least 100 times, at least 200 times, at least 500 times, or at least 1000 times higher than the cleavage rate of the specific cleavage site at a different tissue. In some embodiments, the redox cleavage site is preferentially cleaved in a reducing environment. In some embodiments, the redox cleavage site is preferentially cleaved in a reducing environment relative to blood. In some embodiments, the redox cleavage site is preferentially cleaved in a reducing environment relative to interstitial fluid. In some embodiments, the redox cleavage site is preferentially cleaved in a reducing environment relative to lymph fluid. In some embodiments, the redox cleavage site is preferentially cleaved in a reducing environment of the tumor microenvironment.

[0152] pH cleavable artificial end moiety

[0153] The pH of circulating blood is buffered within a narrow range between 7.31 and 7.45. Changes outside this range usually result in acidosis or alkalosis, which are serious medical concerns. The tumor microenvironment is characterized by being more acidic than the circulating blood pH due to a metabolic dysregulation in tumor cells called the Warburg effect: growing tumor cells exhibit a high rate of glycolysis followed by fermentation of pyruvate to lactate in the cytoplasm rather than oxidation of pyruvate in the mitochondrial TCA cycle. To maintain the cytoplasmic pH, tumor cells transport hydrogen ions to the extracellular environment, creating an acidic tumor microenvironment.

[0154] In some embodiments, the specific cleavage site is a pH-sensitive cleavage site. In some embodiments, the pH-sensitive cleavage site is selected to preferentially cleave at the target tissue. In some embodiments, the target tissue is associated with a specific pH or a pH difference compared to other local tissues.

[0155] In some embodiments, the pH sensitive cleavage site is cleaved at a pH below physiological blood pH (e.g., below about 7.3). In some embodiments, the pH sensitive cleavage site is preferentially cleaved at a pH below 7.3, below 7.2, below 7.1, or below 7.0. In some embodiments, the pH sensitive cleavage site is preferentially cleaved at an acidic pH. In some embodiments, the pH sensitive cleavage site is preferentially cleaved at a pH below 7, 6.5, 6, 5.5, or 5.

[0156] In some embodiments, the pH-sensitive cleavage site is preferentially cleaved at or near a target tissue in a subject such that the cleavage rate of the specific cleavage site is at least 2-fold, at least 4-fold, at least 8-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 50-fold, at least 100-fold, at least 200-fold, at least 500-fold, or at least 1000-fold higher than the cleavage rate of the specific cleavage site at a different tissue. In some embodiments, the target tissue is a tumor microenvironment.

[0157] Closed part

[0158] In some embodiments, the artificial end portion comprises a blocking moiety. In some embodiments, the blocking moiety is a group that, when attached to the IL-18 polypeptide in an Act-IL-18 polypeptide, serves to disrupt or inhibit the binding of the IL-18 polypeptide to the IL-18 receptor or a subunit thereof (e.g., as measured by an assay designed to detect binding or by an in vitro or in vivo activity assay of the Act-IL-18 polypeptide).

[0159] In some embodiments, the blocking moiety is a steric blocking group or a specific blocking group. In some embodiments, the blocking moiety is a steric blocking group. In some embodiments, the steric blocking group does not specifically interact with the IL-18 polypeptide, but due to its large size, its presence will hinder the interaction of the Act-IL-18 polypeptide with the receptor. In some embodiments, the steric blocking group is a polymer (e.g., polyethylene glycol) or a polypeptide (e.g., albumin, Fc region, etc.).

[0160] In some embodiments, the blocking moiety is a specific blocking group. In some embodiments, the specific blocking group has specific binding or other interactions with IL-18. Non-limiting examples of specific blocking groups may include IL-18 propeptide, antibodies or antigen binding fragments that bind IL-18, IL-18 receptor subunits or domains or other fragments thereof, IL-18 binding proteins or fragments thereof, or other groups that can specifically bind IL-18.

[0161] In some embodiments, the blocking moiety is a propeptide of IL- 18. Endogenously, human IL-18 is expressed as an immature, inactive 193 amino acid sequence of MAAEPVEDN CINFVAMKFIDNTLYFIAEDDENLESDYFGKLESKLSVIRNLNDQVLFIDQGNRPLFEDMTDSDCRDNAPRTIFIISMYKDSQPRGMAVTISVKCEKISTLSCENKIISFKEMNPPDNIKDTKSDIIFFQRSVPGHDNKMQFESSSYEGYFLACEKERDLFKLILKKEDELGDRSIMFTVQNED (SEQ ID NO: 88), the first 36 amino acids of which are a propeptide that can be cleaved by caspase to produce the mature active form of IL-18 (SEQ ID NO: 1). In some embodiments, the IL-18 propeptide blocking portion is attached to the N-terminus of the IL-18 polypeptide (e.g., via a cleavable peptide comprising a specific cleavage site and any optional linker peptide), and in some embodiments, the propeptide or a variant thereof is incorporated into Act-IL-18 as a blocking portion. In some embodiments, the blocking portion is a human IL-18 propeptide or a variant thereof. In some embodiments, the blocking portion is an IL-18 propeptide comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence shown in SEQ ID NO: 89. In some embodiments, the blocking portion is an IL-18 propeptide having a sequence at least 95% identical to the sequence shown in SEQ ID NO: 89. In some embodiments, the blocking portion is an IL-18 propeptide comprising the sequence shown in SEQ ID NO: 89. In some embodiments, the blocking moiety is an IL-18 propeptide comprising the sequence set forth in SEQ ID NO: 89, with a substitution of residue C10 (e.g., a C10S substitution (SEQ ID NO: 90) or a C10A substitution (SEQ ID NO: 91)). In some embodiments, the IL-18 propeptide comprises one or more modifications (e.g., amino acid substitutions) that reduce the affinity of the IL-18 propeptide for the IL-18 polypeptide in the Act-IL-18 polypeptide. In some embodiments where the blocking moiety is an IL-18 propeptide, the specific cleavage site of the Act-IL-18 polypeptide is different from that of the endogenous propeptide (i.e., the specific cleavage site is not the bond between D36 and Y37 of SEQ ID NO: 88). In some embodiments, the IL-18 propeptide acting as a blocking moiety is linked to the N-terminus of the IL-18 polypeptide in the Act-IL-18 polypeptide via another protease recognition sequence (and optionally one or more connecting peptides).

[0162] In some embodiments, the blocking moiety is an IL-18 propeptide (e.g., a human IL-18 propeptide) directly linked to the N-terminus of the IL-18 polypeptide. In some embodiments, the modified IL-18 propeptide comprises a modification that changes the native caspase cleavage site of SEQ ID NO: 88 to a site cleaved by another protease (e.g., any protease provided herein, such as a matrix metalloprotease). In some embodiments, the three C-terminal amino acids of the IL-18 propeptide are substituted with -PLG. In some embodiments, the IL-18 propeptide comprises a -PLG substitution and

[0163] Exemplary IL-18 propeptide sequences

[0164] SEQ ID Closed partial sequence 89 MAAEPVEDNCINFVAMKFIDNTLYFIAEDDENLESD 90 MAAEPVEDNSINFVAMKFIDNTLYFIAEDDENLESD 91 MAAEPVEDNAINFVAMKFIDNTLYFIAEDDENLESD 92 MAAEPVEDNCINFVAMKFIDNTLYFIAEDDENLPLG

[0165] In some embodiments, the Act-IL-18 polypeptide comprising a human IL-18 propeptide or a variant thereof as a blocking portion exhibits significantly reduced activity (e.g., substantially no activity, or activity reduction of more than 1000 times) compared to an activated form of a single IL-18 polypeptide or IL-18 polypeptide. In some embodiments, it may be desirable that the Act-IL-18 connected to the IL-18 propeptide retains higher activity before activation. To achieve this, in some embodiments, it may be advantageous to use an IL-18 propeptide from a non-human species. In some embodiments, the Act-IL-18 polypeptide provided herein comprises an IL-18 propeptide from a non-human species. In some embodiments, the non-human species is a mammal. In some embodiments, the non-human species is a primate, a rodent, an equine, a bovine, a porcine, an equine, a chiropteran, a camelid, or other animals. In some embodiments, the non-human IL-18 propeptide has an amino acid sequence that is at least 50%, 60%, 70% or 75% identical to SEQ ID NO: 89.

[0166] In some embodiments, the blocking portion comprises a portion (e.g., a domain or a portion thereof) of an IL-18 receptor subunit, or a variant thereof. In some embodiments, a portion of an IL-18 receptor subunit or a variant thereof is connected to the C-terminus of an IL-18 polypeptide in an Act-IL-18 polypeptide (e.g., by a cleavable peptide comprising a specific cleavage site and any optional linker peptide). In some embodiments, the blocking portion comprises a portion of an IL-18 receptor α subunit or an IL-18 receptor β subunit, or a variant thereof. In some embodiments, the blocking portion comprises a portion of an IL-18 receptor α subunit, or a variant thereof. In some embodiments, the blocking portion comprises a domain of an IL-18 receptor α subunit, or a variant thereof. In some embodiments, the blocking portion comprises an extracellular domain of an IL-18 receptor α subunit, or a variant thereof. In some embodiments, the blocking portion comprises a D1, D2, or D3 domain of an IL-18 receptor α subunit, or a variant thereof.

[0167] In some embodiments, the blocking portion comprises the D3 domain of the IL-18 receptor alpha subunit, or a variant thereof. The sequence of the human D3 domain of the IL-18 receptor alpha subunit is shown in SEQ ID NO:93 below. In some embodiments, the blocking portion comprises an amino acid sequence having at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence shown in SEQ ID NO:93. In some embodiments, the blocking portion comprises an amino acid sequence having at least 95% sequence identity with the sequence shown in SEQ ID NO:93. In some embodiments, the blocking portion comprises the sequence shown in SEQ ID NO:93. In some embodiments, the blocking portion D3 domain of the IL-18 receptor alpha subunit comprises a substitution that removes a glycosylation site from the D3 domain. In some embodiments, the blocking portion comprises the amino acid sequence shown in SEQ ID NO:94 below.

[0168]

[0169] In some embodiments, when used as a blocking moiety, it may be desirable to introduce one or more amino acid substitutions into the sequence of the D3 domain of the IL-18 receptor α subunit to enhance or reduce the binding of the D3 domain to the IL-18 polypeptide in the Act-IL-18 polypeptide.

[0170] The full-length human IL-18 receptor alpha subunit has the sequence MNCRELPTLWVLISVSTAE SCTSRPHITVVEGEPFYLKHCSCSLAHEIETTTKSWYKSSGSQEHVELNPRSSSRIALHDCVLEFWPVELNDTGSYFFQMKNYTQKWKLNVIRRNKHSCFTERQVTSKIVEVKKFFQITCENSYYQTLVNS TSLYKNCKKLLLENNNKNPTIKKNAEFEDQGYYSCVHFLHHNGKLFNITKTFNITIVEDRSNIVPVLLGPKLNHVAVELGKNVRLNCSALLNEEDVIYWMFGEENGSDPNIHEEKEMRIMTPEGKWHASKVL RIENIGESNLNVLYNCTVASTGGTDTKSFILVRKADMADIPGHVFTRGMIIAVLILVAVVCLVTVCVIYRVDLVLFYRHLTRRDETLTDGKTYDAFVSYLKECRPENGEEHTFAVEILPRVLEKHFGYKLC IFERDVVPGGAVVDEIHSLIEKSRRLIIVLSKSYMSNEVRYELESGLHEALVERKIKIILIEFTPVTDFTFLPQSLKLLKSHRVLKWKADKSLSYNSRFWKNLLYLMPAKTVKPGRDEPEVLPVLSES(SEQ ID NO:95) (UniProt ID: Q13478).

[0171] Connector Peptide

[0172] In some embodiments, the artificial end portion comprises one or more connecting peptides. In some embodiments, the connecting peptide of the artificial end portion is located between the specific cleavage site and the IL-18 polypeptide (i.e., the connecting peptide remains connected to the IL-18 polypeptide after cleavage) or is positioned between the specific cleavage site and the blocking portion, or both (e.g., the Act-IL-18 polypeptide has two connecting peptides). In some embodiments, the connecting peptide comprises 1 to 50 amino acids, 1 to 40 amino acids, 1 to 30 amino acids, 1 to 25 amino acids, 1 to 20 amino acids, 1 to 15 amino acids, 1 to 10 amino acids, or 1 to 5 amino acids. In some embodiments, the connecting peptide comprises 1 to 15 amino acids. In some embodiments, the connecting peptide consists of the amino acids glycine and serine. In some embodiments, the connecting peptide consists of glycine. Non-limiting examples of connecting peptides include, but are not limited to (GS) n (SEQ ID NO: 235), (GGS)n (SEQ ID NO: 236), (GGGS) n (SEQ ID NO: 237), (GGSG) n (SEQ ID NO: 238) or (GGSGG) n (SEQ ID NO: 239), (GGGGS) n (SEQ ID NO: 240), wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. For example, the connecting peptide can be (GGGGS)3 (SEQ ID NO: 241) or (GGGGS)4 (SEQ ID NO: 242). Additional connecting peptides may include GGGGSGGGGSGGGG (SEQ ID NO: 243). In embodiments where the artificial end portion comprises a plurality of connecting peptides, each connecting peptide may be the same or different.

[0173] Molecular orientation

[0174] The Act-IL-18 polypeptides provided herein can have a variety of orientations. In some embodiments, the Act-IL-18 polypeptides provided herein comprise an orientation according to any of the following formulas:

[0175] (a) IL-18-CS;

[0176] (b) IL-18-LP1-CS;

[0177] (c) IL-18-LP1-CS-LP2-BM;

[0178] (d) IL-18-CS-LP1-BM;

[0179] (e) IL-18-CS-BM;

[0180] (f) IL-18-LP1-CP-BM;

[0181] (g) BM-CS-IL-18;

[0182] (h) BM-LP1-CS-IL-18;

[0183] (i) BM-LP1-CS-LP2-IL-18;

[0184] (j) BM-CS-LP1-IL-18;

[0185] (k) CS-LP1-IL-18; and

[0186] (l) CS-IL-18;

[0187] wherein IL-18 is an IL-18 polypeptide, CS is a portion comprising a specific cleavage site (e.g., a protease recognition sequence), LP1 is a first connecting peptide, LP2 is a second connecting peptide, wherein BM is a blocking portion, and wherein the orientation is shown in order from N-terminus to C-terminus.

[0188] In some embodiments, the Act-IL-18 polypeptide comprises an orientation of formula (a). In some embodiments, the Act-IL-18 polypeptide comprises an orientation of formula (b). In some embodiments, the Act-IL-18 polypeptide comprises an orientation of formula (c). In some embodiments, the Act-IL-18 polypeptide comprises an orientation of formula (d). In some embodiments, the Act-IL-18 polypeptide comprises an orientation of formula (e). In some embodiments, the Act-IL-18 polypeptide comprises an orientation of formula (f). In some embodiments, the Act-IL-18 polypeptide comprises an orientation of formula (g). In some embodiments, the Act-IL-18 polypeptide comprises an orientation of formula (h). In some embodiments, the Act-IL-18 polypeptide comprises an orientation of formula (i). In some embodiments, the Act-IL-18 polypeptide comprises an orientation of formula (j). In some embodiments, the Act-IL-18 polypeptide comprises an orientation of formula (k). In some embodiments, the Act-IL-18 polypeptide comprises an orientation of formula (l).

[0189] IL-18 peptide

[0190] Act-IL-18 polypeptides herein include IL-18 polypeptides. The IL-18 polypeptides disclosed herein may contain various modifications to WT IL-18 (SEQ ID NO: 1), including but not limited to amino acid substitutions, deletions, additions, or attachment of polymer moieties.

[0191] In some embodiments, the IL-18 polypeptide comprises an amino acid sequence having at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1. In some embodiments, the IL-18 polypeptide comprises an amino acid sequence having at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any one of SEQ ID NOs: 2-67. In some embodiments, the IL-18 polypeptide comprises an amino acid sequence having at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any one of SEQ ID NOs: 79-83. In some embodiments, the IL-18 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-18 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 79. In some embodiments, the IL-18 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 80. In some embodiments, the IL-18 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 81. In some embodiments, the IL-18 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 82. In some embodiments, the IL-18 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 83.

[0192] Amino Acid Substitutions of IL-18 Peptides

[0193] In some embodiments, the IL-18 polypeptides of the Act-IL-18 polypeptides described herein include polypeptides having at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9 or more substitutions at one or more amino acid residues, wherein the positions of the substitutions are relative to the IL-18 of SEQ ID NO: 1. In some embodiments, the IL-18 polypeptide comprises 1 to 9 amino acid substitutions. In some embodiments, the Act-IL-18 polypeptide comprises 1 or 2 amino acid substitutions, 1 to 3 amino acid substitutions, 1 to 4 amino acid substitutions, 1 to 5 amino acid substitutions, 1 to 6 amino acid substitutions, 1 to 7 amino acid substitutions, 1 to 8 amino acid substitutions, 2 to 3 amino acid substitutions, 2 to 4 amino acid substitutions, 2 to 5 amino acid substitutions, 2 to 6 amino acid substitutions, 2 to 7 amino acid substitutions, 2 to 8 amino acid substitutions, 2 to 9 amino acid substitutions, 3 or 4 amino acid substitutions, 3 to 5 amino acid substitutions, 3 to 6 amino acid substitutions, 3 to 7 amino acid substitutions, 3 to 9 amino acid substitutions, 4 or 5 amino acid substitutions, 4 to 6 amino acid substitutions, 4 to 7 amino acid substitutions, 4 to 9 amino acid substitutions, 5 or 6 amino acid substitutions, 5 to 7 amino acid substitutions, 5 to 9 amino acid substitutions, 6 or 7 amino acid substitutions, 6 to 9 amino acid substitutions, or 7 to 9 amino acid substitutions. In some embodiments, the IL-18 polypeptide comprises 3 amino acid substitutions, 4 amino acid substitutions, 5 amino acid substitutions, 6 amino acid substitutions, 7 amino acid substitutions, or 9 amino acid substitutions. In some embodiments, the IL-18 polypeptide further comprises additional substitutions to the synthetic IL-18 polypeptide (e.g., homoserine substitutions, norleucine substitutions, O-methyl-homoserine substitutions, other non-natural or modified amino acids). It is expressly contemplated that these substitutions may be included in addition to the substitutions provided in this section (e.g., the synthetic IL-18 polypeptide may comprise 1 to 9 amino acid substitutions discussed above and additional synthetic IL-18 amino acid substitutions).

[0194] In some embodiments, the modified IL-18 polypeptide comprises at least one additional modification to the amino acid sequence of SEQ ID NO: 1 selected from the group consisting of Y01X, F02X, E06X, S10X, V11X, D17X, C38X, M51X, K53X, D54X, S55X, T63X, C68X, E69X, K70X, C76X, E85X, M86X, T95X, D98X, and C127X, wherein each X is independently a natural or unnatural amino acid. In some embodiments, the modified IL-18 polypeptide comprises at least one additional modification to the amino acid sequence of SEQ ID NO: 1 selected from the group consisting of Y01G, F02A, E06K, S10T, V11I, D17N, C38S, C38A, C38Q, M51G, K53A, D54A, S55A, T63A, C68S, C68A, E69C, K70C, C76S, C76A, E85C, M86C, T95C, D98C, C127A, and C127S.

[0195] In one aspect, an Act-IL-18 polypeptide is described herein, comprising a modified IL-18 polypeptide comprising E06K and K53A, wherein the residue position numbering of the modified IL-18 polypeptide is based on SEQ ID NO: 1 as a reference sequence. In some embodiments, the modified IL-18 polypeptide further comprises T63A. In some embodiments, the modified IL-18 polypeptide further comprises at least one of Y01X, S55X, F02X, D54X, C38X, C68X, E69X, K70X, C76X, or C127X, wherein each X is independently an amino acid or an amino acid derivative. In some embodiments, the modified IL-18 polypeptide further comprises at least one of Y01G, S55A, F02A, D54A, C38S, C38A, C68S, C68A, K70C, C76S, C76A, C127S, or C127A.

[0196] In some embodiments, the modified IL-18 peptide comprises at least one modification to the amino acid sequence of SEQ ID NO: 1, wherein the modification is E06X, K53X, S55X or T63X, wherein X is a natural or non-natural amino acid. In some embodiments, the modified IL-18 peptide comprises at least two additional modifications to the amino acid sequence of SEQ ID NO: 1, wherein the modifications include E06X and K53X; E06X and S55X; K53X and S55X; E06X and T63X; or K53X and T63X, wherein X is a natural or non-natural amino acid. In some embodiments, the modified IL-18 peptide comprises at least three additional modifications to the amino acid sequence of SEQ ID NO: 1, wherein the modifications include E06X, K53X and S55X; or E06X, K53X and T63X, wherein X is a natural or non-natural amino acid. In some embodiments, the modified IL-18 peptide comprises at least four additional modifications to the amino acid sequence of SEQ ID NO: 1, wherein the modifications include E06X, K53X, S55X and T63X; E06X, K53X, S55X and Y01X; E06X, K53X, S55X and F02X; E06X, K53X, S55X and D54X; E06X, K53X, S55X and M51X; or C38X, C68X, C76X and C127X, wherein X is a natural or unnatural amino acid. In each embodiment in which multiple amino acid residues are replaced with natural or unnatural amino acids X, each X is independently the same or different amino acids.

[0197] In some embodiments, the modified IL-18 peptide comprises at least one additional modification to the amino acid sequence of SEQ ID NO: 1, wherein the modification is E06K, V11I, K53A, S55A or T63A. In some embodiments, the modified IL-18 peptide comprises at least two additional modifications to the amino acid sequence of SEQ ID NO: 1, wherein the modifications include E06K and K53A; E06K and S55A; K53A and S55A; E06K and T63A; or K53A and T63A. In some embodiments, the modified IL-18 peptide comprises at least three additional modifications to the amino acid sequence of SEQ ID NO: 1, wherein the modifications include E06K, K53A and S55A; E06K, V11I and K53A; E06K, C38A and K53A; or E06K, K53A and T63A. In some embodiments, the modified IL-18 peptide comprises at least four additional modifications to the amino acid sequence of SEQ ID NO: 1, wherein the modifications include E06K, K53A, S55A and T63A; E06K, K53A, S55A and Y01G; E06K, K53A, S55A and F02A; E06K, K53A, S55A and D54A; E06K, K53A, S55A and M51G; or C38S, C68S, C76S and C127S. In some embodiments, the modified IL-18 peptide comprises at least six modifications to the amino acid sequence of SEQ ID NO: 1, wherein the modifications include E06K, K53A, C38S, C68S, C76S and C127S; or K53A, T63A, C38S, C68S, C76S and C127S. In some embodiments, the modified IL-18 polypeptide comprises at least seven modifications to the sequence of SEQ ID NO: 1, wherein the seven modifications include E6K, V11I, C38A, K53A, T63A, C76A, C127A. In some embodiments, the modified IL-18 peptide comprises at least eight modifications to the amino acid sequence of SEQ ID NO: 1, wherein the modifications include Y01G, F02A, E06K, M51G, K53A, D54A, S55A and T63A. In some embodiments, the modified IL-18 peptide comprises at least eight additional modifications to the amino acid sequence of SEQ ID NO: 1, wherein the modifications include Y01G, F02A, E06K, M51G, K53A, D54A, S55A and T63A.

[0198] In one aspect, provided herein is a modified IL-18 polypeptide having a polymer as provided herein (e.g., a polymer linked to a residue as provided herein), the modified IL-18 polypeptide further comprising E06K and K53A, wherein the residue position numbering of the modified IL-18 polypeptide is based on SEQ ID NO: 1 as a reference sequence. In some embodiments, the modified IL-18 polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to the amino acid sequence of SEQ ID NO: 30. In some embodiments, the modified IL-18 polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to the amino acid sequence of SEQ ID NO: 59. In some embodiments, the modified IL-18 polypeptide further comprises an amino acid substitution at one or more cysteine ​​residues. In some embodiments, the modified IL-18 polypeptide comprises one or more cysteines substituted with serine or alanine. In some embodiments, the modified IL-18 polypeptide comprises an amino acid substitution at each cysteine ​​residue of SEQ ID NO: 1. In some embodiments, each cysteine ​​residue is replaced by serine or alanine. In some embodiments, the modified IL-18 polypeptide comprises a polymer covalently linked to an amino acid residue. In some embodiments, the modified IL-18 polypeptide comprises an amino acid replacement at 1, 2, 3, 4, 5 or 6 methionine residues. In some embodiments, each replacement at a methionine residue is an O-methyl-L-homoserine residue or a norleucine residue. In some embodiments, each methionine residue is replaced by an O-methyl-L-homoserine residue. In some embodiments, the modified IL-18 polypeptide comprises a homoserine residue at one of positions 31, 116, and 63 and 75. In some embodiments, the modified IL-18 polypeptide comprises a homoserine residue at one of positions 31, 116, 75, and 50, 57, 63, and 67. In some embodiments, the modified IL-18 polypeptide comprises a homoserine residue at one of positions 31, 121, 75, and 50, 57, 63, and 67.

[0199] The IL-18 polypeptide of the Act-IL-18 polypeptide as described herein may comprise one or more atypical amino acids. An "atypical" amino acid may refer to an amino acid residue that is not a D-form or an L-form of the 20 typical amino acids that are usually incorporated into naturally occurring proteins. In some embodiments, one or more amino acids of the active form of the Act-IL-18 polypeptide are substituted with one or more atypical amino acids. Atypical amino acids include, but are not limited to, N-α-(9-Fmoc)-L-azidolysine (Fmoc-L-Lys(N3)-OH), N-α-(9-Fmoc)-L-biphenylalanine (Fmoc-L-Bip-OH), and N-α-(9-Fmoc)-O-benzyl-L-tyrosine (Fmoc-L-Tyr(Bzl)-OH).

[0200] Exemplary atypical amino acids include azido-lysine (AzK), hydroxylysine, allohydroxylysine, ε-N,N,N-trimethyllysine, ε-N-acetyllysine, 5-hydroxylysine, Fmoc-Lys(Me,Boc), Fmoc-Lys(Me)3, Fmoc-Lys(palmitoyl), Fmoc-L-photo-lysine, DL-5-hydroxylysine, HL-photo-lysine and / or other similar amino acids. Exemplary atypical amino acids also include D-methionine, selenocysteine ​​and / or other similar amino acids.

[0201] Exemplary atypical amino acids also include p-acetyl-L-phenylalanine, p-iodo-L-phenylalanine, p-methoxyphenylalanine, O-methyl-L-tyrosine, p-propargyloxyphenylalanine, p-propargyl-phenylalanine, L-3-(2-naphthyl)alanine, 3-methyl-phenylalanine, O-4-allyl-L-tyrosine, 4-propyl-L-tyrosine, tri-O-acetyl-GlcNAcp-serine, L-DOPA, fluorinated phenylalanine, isopropyl-L-phenylalanine, p-azido-L-phenylalanine, p-acyl-L-phenylalanine, p-benzoyl-L-phenylalanine, p-boronophenylalanine, O-propargyltyrosine, L-phosphoserine, phosphoserine, phosphotyrosine, p- Analogs of bromophenylalanine, p-amino-L-phenylalanine, isopropyl-L-phenylalanine, tyrosine amino acids; Analogs of glutamine amino acids; Analogs of phenylalanine amino acids; Analogs of serine amino acids; Analogs of threonine amino acids; Alkyl, aryl, acyl, azido, cyano, halogen, hydrazine, hydrazide, hydroxyl, alkenyl, alkynyl, ether, thiol, sulfonyl, seleno, ester, thioacid, borate, boronate, phosphate, phosphono, phosphine, heterocycle, enone, imine, aldehyde, hydroxylamine, keto or amino substituted amino acids, β-amino acids; Cyclic amino acids other than proline or histidine; Aromatic amino acids other than phenylalanine, tyrosine or tryptophan; Or combinations thereof. In some embodiments, atypical amino acids are selected from β-amino acids, homoamino acids, cyclic amino acids, and amino acids with derivatized side chains. In some embodiments, atypical amino acids include β-alanine, β-alanine, pipecolic acid, aminocaproic acid, aminoheptanoic acid, aminopimelic acid, desmosine, diaminopimelic acid, N α -Ethylglycine, N α -Ethylasparagine, isodesmosine, alloisoleucine, ω-methylarginine, N α -methylglycine, N α -methylisoleucine, N α -methylvaline, γ-carboxyglutamate, O-phosphoserine, N α -Acetylserine, N α -formylmethionine, 3-methylhistidine and / or other similar amino acids.

[0202] In some embodiments, an amino acid residue of an Act-IL-18 polypeptide is replaced with a modified lysine residue. In some embodiments, the modified lysine residue comprises an amino, azide, allyl, ester, and / or amide functional group. In some embodiments, the modified lysine residue contains a conjugation handle that can serve as a useful anchor point to attach additional moieties to the active form of the Act-IL-18 polypeptide. In some embodiments, the modified lysine residue has a structure constructed from Precursor Structure 1, Structure 2, Structure 3, or Structure 4:

[0203]

[0204] In some embodiments, the Act-IL-18 polypeptide contains a substitution of modified amino acid residues that can be used for the attachment of additional functional groups that can be used to facilitate the conjugation reaction or attachment of various payloads (e.g., polymers) to the Act-IL-18 polypeptide. The substitution can be a derivative of a naturally occurring amino acid (e.g., aspartic acid, cysteine, glutamic acid, lysine, serine, threonine, or tyrosine) that is more amenable to attachment of additional functional groups, a modified version of any naturally occurring amino acid, or any non-natural amino acid (e.g., an amino acid containing a desired reactive group such as a click chemistry reagent such as an azide, an alkyne, etc.). Non-limiting examples of such modified amino acid residues include modified lysine, glutamic acid, aspartic acid, and cysteine ​​provided below:

[0205]

[0206] wherein each n is an integer from 1 to 30. These non-limiting examples of modified amino acid residues can be used at any position where it is desired to add additional functional groups (eg, polymers) to the Act-IL-18 polypeptide.

[0207] In some embodiments, any of the structures 1-4 provided above, modified lysine, modified glutamic acid, modified aspartic acid, or modified cysteine ​​can be substituted for different residues of the Act-IL-18 polypeptide (e.g., any of residues 68-70 or residues 80-100 using SEQ ID NO: 1 as a reference sequence) to allow conjugation at different sites of the IL-18 polypeptide. The azide functional group can also be replaced with another suitable conjugation handle.

[0208] The conjugation handles provided herein can be any suitable reactive group capable of reacting with a complementary reactive group. In some embodiments, the conjugation handles include reagents for Cu(I)-catalyzed or "copper-free" alkyne-azidetriazole formation reactions (e.g., stress-promoted cycloadditions), Staudinger ligation, inverse electron demand Diels-Alder (IEDDA) reactions, "photoclick" chemistry, tetrazine cycloadditions with trans-cyclooctene, potassium acyl trifluoroborate (KAT) ligation, or metal-mediated processes such as olefin metathesis and Suzuki-Miyaura or Sonogashira cross-couplings.

[0209] In some embodiments, the conjugation handle includes a reagent for a "copper-free" alkyne azide triazole formation reaction. Non-limiting examples of alkynes for use in the alkyne azide triazole formation reaction include cyclooctyne reagents (e.g., reagents containing (1R, 8S, 9s)-bicyclo[6.1.0]non-4-alkyn-9-ylmethanol, dibenzocyclooctyne-amine reagents, difluorocyclooctyne, or derivatives thereof).

[0210] In some embodiments, the conjugation handle comprises a reactive group selected from the group consisting of azide, alkyne, tetrazine, halide, sulfhydryl, disulfide, maleimide, activated ester, olefin, aldehyde, ketone, imine, hydrazine, acyl trifluoroborate, hydroxylamine, phosphine, trans-cyclooctene, and hydrazide. In some embodiments, the conjugation handle and the complementary conjugation handle comprise a "click" chemistry reagent. Exemplary groups of click chemistry residues are shown in Hein et al., “Click Chemistry, A Powerful Tool for Pharmaceutical Sciences,” Pharmaceutical Research, Vol. 25, pp. 2216-2230 (2008); Thirumurugan et al., “Click Chemistry for Drug Development and Diverse Chemical-Biology Applications,” Chem. Rev. 2013, 113, 7, 4905-4979; US20160107999A1; US10266502B2; and US20190204330A1, each of which is incorporated by reference in its entirety.

[0211] In some embodiments, the group (e.g., polymer moiety or another polypeptide) attached to the Act-IL-18 polypeptide comprises a conjugation handle or a reaction product of a conjugation handle and a complementary conjugation handle. In some embodiments, the reaction product of a conjugation handle and a complementary conjugation handle is produced by a KAT ligation (reaction of potassium acyl trifluoroborate with hydroxylamine), a Staudinger ligation (reaction of an azide with a phosphine), a tetrazine cycloaddition (reaction of a tetrazine with trans-cyclooctene), or a Huisgen cycloaddition (reaction of an alkyne with an azide). In some embodiments, the group (e.g., polymer or another polypeptide) attached to the IL-18 polypeptide will comprise the reaction product of a conjugation handle and a complementary conjugation handle, which is used to attach the group to the Act-IL-18 polypeptide.

[0212] Polymers linked to Act-IL-18 polypeptides

[0213] In one aspect, described herein is a polypeptide comprising an Act-IL-18 polypeptide, wherein the Act-IL-18 polypeptide comprises a covalently linked polymer. In some embodiments, the Act-IL-18 polypeptide described herein comprises one or more polymers covalently linked thereto. In some embodiments, the Act-IL-18 polypeptide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more polymers covalently linked to the Act-IL-18 polypeptide.

[0214] In some embodiments, the polymer comprises a conjugation handle that can be used to further attach additional moieties to the Act-IL-18 polypeptide (e.g., adding additional polypeptides, such as antibodies). Any suitable reactive group capable of reacting with a complementary reactive group attached to another moiety can be used as a conjugation handle. In some embodiments, the conjugation handle comprises reagents for Cu(I)-catalyzed or "copper-free" alkyne-azidetriazole formation reactions (e.g., stress-promoted cycloadditions), Staudinger ligation, inverse electron demand Diels-Alder (IEDDA) reactions, "photoclick" chemistry, tetrazine cycloadditions with trans-cyclooctene, potassium acyl trifluoroborate (KAT) ligation, or metal-mediated processes such as olefin metathesis and Suzuki-Miyaura or Sonogashira cross-couplings.

[0215] In some embodiments, the IL-18 polypeptide comprises a polymer attached to a residue of the IL-18 polypeptide. In some embodiments, the polymer is attached to any one of residues 30-157 of the IL-18 polypeptide. In some embodiments, the polymer is covalently attached to a residue selected from residues 38, 68, 69, 70, 76, 78, 85, 86, 95, 98, 121, 127, and 144 of the IL-18 polypeptide. In some embodiments, the polymer is covalently attached to a residue selected from residues 68, 69, 70, 85, 86, 95, and 98 of the IL-18 polypeptide. In some embodiments, the polymer is covalently attached to residue 68 of the IL-18 polypeptide. In some embodiments, the polymer is covalently attached to residue 68 of the IL-18 polypeptide. In some embodiments, the polymer is covalently attached to residue 69 of the pro-IL-18 polypeptide. In some embodiments, the polymer is covalently attached to residue 70 of the IL-18 polypeptide. In some embodiments, the polymer is covalently attached to residue 85 of the IL-18 polypeptide. In some embodiments, the polymer is covalently linked to the IL-18 polypeptide at residue 86. In some embodiments, the polymer is covalently linked to the IL-18 polypeptide at residue 98.

[0216] In some embodiments, the polymer is covalently linked to residue 85. In some embodiments, the polymer is covalently linked to residue E85, E85C, E85D, E85Q, E85K, E85N, or E85Y. In some embodiments, the polymer is covalently linked to residue E85. In some embodiments, the polymer is covalently linked to residue E85C. In some embodiments, the polymer is covalently linked to the non-natural amino acid at residue 85.

[0217] In some embodiments, the polymer is covalently linked to residue 86. In some embodiments, the polymer is covalently linked to residues M86C, M86D, M86Q, M86K, M86N, M86E, or M86Y. In some embodiments, the polymer is covalently linked to M86C. In some embodiments, the polymer is covalently linked to the non-natural amino acid at residue 86.

[0218] In some embodiments, the polymer is covalently linked to residue 95. In some embodiments, the polymer is covalently linked to residues T95, T95C, T95D, T95Q, T95K, T95N, T95E, or T95Y. In some embodiments, the polymer is covalently linked to residues T95C, T95D, T95Q, T95K, T95N, T95E, or T95Y. In some embodiments, the polymer is covalently linked to residue T95C. In some embodiments, the polymer is covalently linked to the non-natural amino acid at residue 95.

[0219] In some embodiments, the polymer is covalently linked to residue 98. In some embodiments, the polymer is covalently linked to residue D98, D98C, D98Q, D98K, D98N, D98E, or D98Y. In some embodiments, the polymer is covalently linked to residue D98C. In some embodiments, the polymer is covalently linked to the non-natural amino acid at residue 98.

[0220] In one aspect, provided herein is an Act-IL-18 polypeptide having a polymer as provided herein (e.g., a polymer linked to a residue as provided herein), the Act-IL-18 polypeptide further comprising E06K and K53A, wherein the residue position numbering of the Act-IL-18 polypeptide is based on SEQ ID NO: 1 as a reference sequence. In some embodiments, the Act-IL-18 polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to the amino acid sequence of SEQ ID NO: 30. In some embodiments, the Act-IL-18 polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to the amino acid sequence of SEQ ID NO: 59. In some embodiments, the Act-IL-18 polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to the amino acid sequence of SEQ ID NO: 59. In some embodiments, the Act-IL-18 polypeptide further comprises an amino acid substitution at one or more cysteine ​​residues. In some embodiments, the Act-IL-18 polypeptide comprises one or more cysteines substituted with serine or alanine. In some embodiments, the Act-IL-18 polypeptide comprises an amino acid substitution at each cysteine ​​residue of SEQ ID NO: 1. In some embodiments, each cysteine ​​residue is substituted with serine or alanine. In some embodiments, the Act-IL-18 polypeptide comprises a polymer covalently linked to an amino acid residue.

[0221] Active form of IL-18 peptide

[0222] In some embodiments, cleavage of the specific cleavage site of the artificial end portion converts Act-IL-18 into an active form of the IL-18 polypeptide. As used herein, an active form of an IL-18 polypeptide refers to a cleaved form of the IL-18 polypeptide that has some or all of the activity associated with an IL-18 polypeptide inactivated by the artificial end portion. In addition, unless the context clearly indicates otherwise, simply referring to an "IL-18 polypeptide" refers to an IL-18 polypeptide that has never been prepared in an activatable form (e.g., it refers to the base IL-18 polypeptide on which the Act-IL-18 polypeptide is based). In some embodiments, the active form of the IL-18 polypeptide comprises a portion of the artificial end portion that is still connected to the IL-18 polypeptide (e.g., a subset of the amino acid residues of the artificial end portion). In some embodiments, the active form of the IL-18 polypeptide is identical to the IL-18 polypeptide (e.g., because the entire artificial end portion has been cleaved, it has the same amino acid sequence as the IL-18 polypeptide).

[0223] In some embodiments, the active form of the IL-18 polypeptide provided herein exhibits reduced binding to IL-18 binding protein (IL-18BP) relative to WT-IL-18. The active form of the IL-18 polypeptide may also exhibit IL-18Rαβ binding characteristics that are different from wild-type IL-18 (e.g., higher affinity for IL-18Rαβ heterodimers or lower affinity for IL-18Rαβ heterodimers). In preferred embodiments, the affinity of the active form of the IL-18 polypeptide for IL-18Rαβ is not significantly lower than the affinity of WT IL-18 for IL-18Rαβ (e.g., the affinity of the active form of the Act-IL-18 polypeptide for IL-18Rαβ is not less than about 500x lower than that of wild-type IL-18).

[0224] In some embodiments, the active form of the IL-18 polypeptide exhibits increased affinity for the IL-18 receptor α subunit (IL-18Rα) or IL-18 receptor β subunit (IL-18Rβ) relative to wild-type IL-18. In some embodiments, the active form of the IL-18 polypeptide has increased affinity for the IL-18Rα / β heterodimer relative to IL-18WT. In one aspect, the active form of the IL-18 polypeptide described herein has reduced affinity for the IL-18Rα / β heterodimer relative to wild-type IL-18.

[0225] In some embodiments, the binding affinity between the active form of the IL-18 polypeptide and IL-18Rα is equal to or lower than the binding affinity between wild-type IL-18 and IL-18Rα. In some embodiments, the binding affinity between the active form of the IL-18 polypeptide and IL-18Rα is equal to or higher than the binding affinity between wild-type IL-18 and IL-18Rα. In some embodiments, the binding affinity between the active form of the IL-18 polypeptide and IL-18Rβ is equal to or lower than the binding affinity between wild-type IL-18 and IL-18Rβ. In some embodiments, the binding affinity between the active form of the IL-18 polypeptide and IL-18Rβ is equal to or higher than the binding affinity between wild-type IL-18 and IL-18Rβ. In some embodiments, the binding affinity between the active form of the IL-18 polypeptide and IL-18Rα / β heterodimer is equal to or lower than the binding affinity between wild-type IL-18 and IL-18Rα / β heterodimer. In some embodiments, the binding affinity between the active form of the IL-18 polypeptide and the IL-18Rα / β heterodimer is equal to or greater than the binding affinity between wild-type IL-18 and the IL-18Rα / β heterodimer.

[0226] In some embodiments, the active form of the IL-18 polypeptide provided herein exhibits the ability to induce interferon gamma (IFNγ) production after administration to a subject. In some embodiments, the ability to induce IFNγ is comparable to the ability of wild-type IL-18 to induce IFNγ (e.g., exhibiting an EC50 for IFNγ induction within about 10 times the EC50 for IFNγ induction of wild-type IL-18). Exemplary IL-18 polypeptides exhibiting this feature are shown in Figure 5A , the graph shows a comparison of IFNγ production (ng / mL, y-axis) as a function of wild-type and IL-18 polypeptide (mutein) concentrations (nM, x-axis).

[0227] In some embodiments, the active forms of the Act-IL-18 polypeptides provided herein also exhibit reduced binding to IL-18 binding protein (IL-18BP). In some embodiments, the active forms of the IL-18 polypeptides provided herein can induce IFNγ even in the presence of IL-18BP (e.g., the ability of the active forms of the Act-IL-18 polypeptides to induce IFNγ is not substantially limited by the presence of IL-18BP) (nM, x-axis). Examples of IL-18 polypeptides having this property compared to wild-type IL-18 are shown in Figure 5B, which shows the change in IFNγ production (ng / mL, y-axis) as a function of IL-18BP concentration (nM, x-axis) in samples treated with the same level of wild-type IL-18 (circles) or IL-18 polypeptides (inverted triangles). In some embodiments, the active form of the IL-18 polypeptide provided herein exhibits a similar or only slightly reduced ability to induce IFNγ production compared to wild-type IL-18.

[0228] In some embodiments, the active form of the IL-18 polypeptide provided herein exhibits a significant reduction in the inhibition of the ability to induce IFNγ production in the presence of IL-18BP compared to wild-type IL-18. In some embodiments, the active form of the IL-18 polypeptide provided herein exhibits a similar or only slightly reduced ability to induce IFNγ production compared to wild-type IL-18, and a significant reduction in the inhibition of the ability to induce IFNγ production in the presence of IL-18BP compared to wild-type IL-18.

[0229] Biological activity of Act-IL-18 and active forms of IL-18 peptides

[0230] Binding affinity

[0231] In some embodiments, Act-IL-18 exhibits at least 10-fold, at least 100-fold, at least 500-fold, at least 1000-fold lower affinity for the IL-18 receptor than wild-type IL-18 or an active form of an IL-18 polypeptide. In some embodiments, Act-IL-18 exhibits at least 5-fold, at least 10-fold, at least 100-fold, at least 500-fold, at least 1000-fold higher EC for increased IFN-γ production than wild-type IL-18 or an active form of an IL-18 polypeptide. 50 In some embodiments, Act-IL-18 exhibits an increased EC for IFN-γ production that is at least 5-fold, at least 10-fold, at least 100-fold, at least 500-fold, at least 1000-fold greater than an active form of an IL-18 polypeptide. 50 In some embodiments, Act-IL-18 exhibits an increased EC for IFN-γ production that is at least 5-fold, at least 10-fold, at least 100-fold, at least 500-fold, at least 1000-fold greater than that of an IL-18 polypeptide. 50 .

[0232] In some embodiments, the active form of the IL-18 polypeptide provided herein exhibits a reduced affinity for IL-18 binding protein (IL-18BP) compared to WT IL-18 (SEQ ID NO: 1). In some embodiments, the active form of the IL-18 polypeptide exhibits an affinity for IL-18BP that is at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 30-fold, at least 40-fold, at least 50-fold, at least 60-fold, at least 70-fold, at least 80-fold, at least 90-fold, or at least 100-fold lower than WT IL-18. In some embodiments, the active form of the IL-18 polypeptide exhibits an affinity for IL-18BP that is at least 10-fold lower than WT IL-18. In some embodiments, the active form of the IL-18 polypeptide exhibits an affinity for IL-18BP that is at least 20-fold lower than WT IL-18. In some embodiments, the active form of the IL-18 polypeptide exhibits at least 50-fold lower affinity for IL-18BP compared to WT IL-18. In some embodiments, the active form of the IL-18 polypeptide exhibits at least 80-fold lower affinity for IL-18BP compared to WT IL-18. In some embodiments, the active form of the IL-18 polypeptide exhibits at least 100-fold lower affinity for IL-18BP compared to WT IL-18.

[0233] In some embodiments, such as by K D In some embodiments, the active form of the IL-18 polypeptide provided herein exhibits a reduced binding to IL-18BP as measured by IL-18B. In some embodiments, the active form of the IL-18 polypeptide exhibits a Kp of at least about 1 nM, at least about 5 nM, at least about 10 nM, at least about 15 nM, at least about 20 nM, at least about 25 nM, at least about 50 nM, at least about 100 nM, at least about 200 nM, at least about 300 nM, at least about 400 nM, or at least about 500 nM to IL-18BP. D In some embodiments, the active form of the IL-18 polypeptide exhibits a K of at least about 1 nM with IL-18BP. D In some embodiments, the active form of the IL-18 polypeptide exhibits a K of at least about 5 nM with IL-18BP. D In some embodiments, the active form of the IL-18 polypeptide exhibits a K of at least about 50 nM with IL-18BP. D In some embodiments, the active form of the IL-18 polypeptide exhibits a K of at least about 100 nM with IL-18BP. D In some embodiments, the active form of the IL-18 polypeptide exhibits a K of at least about 500 nM with IL-18BP. D .

[0234] In some embodiments, the active form of the IL-18 polypeptide exhibits at most only slightly reduced affinity for IL-18Rαβ compared to WT IL-18 (SEQ ID NO: 1). In some embodiments, the active form of the IL-18 polypeptide exhibits at most 2-fold lower, at most 3-fold lower, at most 4-fold lower, at most 5-fold lower, at most 10-fold lower, at most 15-fold lower, at most 20-fold lower, at most 30-fold lower, at most 40-fold lower, at most 50-fold lower, at most 75-fold lower, or at most 100-fold lower affinity for IL-18Rαβ compared to the affinity of WT IL-18 for IL-18Rαβ. In some embodiments, the active form of the IL-18 polypeptide exhibits at most 10-fold lower affinity for IL-18Rαβ compared to the affinity of WT IL-18 for IL-18Rαβ. In some embodiments, the active form of the IL-18 polypeptide exhibits an affinity for IL-18Rαβ that is up to 20 times lower than the affinity of WT IL-18 for IL-18Rαβ. In some embodiments, the active form of the IL-18 polypeptide exhibits an affinity for IL-18Rαβ that is up to 50 times lower than the affinity of WT IL-18 for IL-18Rαβ. In some embodiments, the active form of the IL-18 polypeptide exhibits an affinity for IL-18Rαβ that is up to 100 times lower than the affinity of WT IL-18 for IL-18Rαβ. In some embodiments, the active form of the IL-18 polypeptide exhibits an increased affinity for IL-18Rαβ compared to WT IL-18. In some embodiments, the affinity is increased by at least 2 times, at least 4 times, at least 6 times, at least 8 times, or at least 10 times compared to WT IL-18.

[0235] In some embodiments, the active form of the IL-18 polypeptide exhibits at most only slightly reduced affinity for IL-18Rαβ compared to the corresponding IL-18 polypeptide without the artificial end portion. In some embodiments, the active form of the IL-18 polypeptide exhibits an affinity for IL-18Rαβ that is at most 2-fold lower, at most 3-fold lower, at most 4-fold lower, at most 5-fold lower, at most 10-fold lower, at most 15-fold lower, at most 20-fold lower, at most 30-fold lower, at most 40-fold lower, at most 50-fold lower, at most 75-fold lower, or at most 100-fold lower than the affinity of the corresponding IL-18 polypeptide without the artificial end portion for IL-18Rαβ. In some embodiments, the active form of the IL-18 polypeptide exhibits an affinity for IL-18Rαβ that is at most 2-fold lower than the affinity of the corresponding IL-18 polypeptide without the artificial end portion for IL-18Rαβ. In some embodiments, the active form of the IL-18 polypeptide exhibits an affinity for IL-18Rαβ that is up to 3 times lower than the affinity of the corresponding IL-18 polypeptide without the artificial terminal portion for IL-18Rαβ. In some embodiments, the active form of the IL-18 polypeptide exhibits an affinity for IL-18Rαβ that is up to 4 times lower than the affinity of the corresponding wild-type IL-18 polypeptide without the N-terminal domain for IL-18Rαβ. In some embodiments, the active form of the IL-18 polypeptide exhibits an affinity for IL-18Rαβ that is up to 5 times lower than the affinity of the corresponding IL-18 polypeptide without the artificial terminal portion for IL-18Rαβ. In some embodiments, the active form of the IL-18 polypeptide exhibits an affinity for IL-18Rαβ that is up to 10 times lower than the affinity of the corresponding IL-18 polypeptide without the artificial terminal portion for IL-18Rαβ.

[0236] In some embodiments, such as by K D The active forms of the IL-18 polypeptides provided herein exhibit at most only a slight reduction in binding to IL-18Rαβ as measured. In some embodiments, the active forms of the IL-18 polypeptides exhibit a Kp of at most about 10 nM, at most about 20 nM, at most about 30 nM, at most about 50 nM, at most about 75 nM, at most about 100 nM, or at most about 200 nM for IL-18Rαβ. D In some embodiments, the active form of the IL-18 polypeptide exhibits a K for IL-18Rαβ of at most about 20 nM. D In some embodiments, the active form of the Act-IL-18 polypeptide exhibits a K for IL-18Rαβ of at most about 30 nM. D In some embodiments, the active form of the IL-18 polypeptide exhibits a K for IL-18Rαβ of at most about 40 nM. DIn some embodiments, the active form of the IL-18 polypeptide exhibits a K for IL-18Rαβ of at most about 50 nM. D In some embodiments, such as by K D The active form of the IL-18 polypeptide exhibits increased binding to IL-18Rαβ as measured by WT IL-18. In some embodiments, the active form of the IL-18 polypeptide has a Kp of IL-18Rαβ. D At most about 2 nM, at most about 1 nM, at most about 0.5 nM, or at most about 0.2 nM.

[0237] In some embodiments, the active form of the IL-18 polypeptide exhibits a wide window in which the active form of the IL-18 polypeptide will bind to IL-18Rαβ even in the presence of IL-18BP. In some embodiments, this window can be determined by the K of the Act-IL-18 / IL-18BP interaction. D K interacting with IL-18 / IL-18Rαβ D In some embodiments, the active form of the IL-18 polypeptide exhibits a K of 1:1 for the IL-18 / IL-18BP interaction. D K interacting with IL-18 / IL-18Rab D The ratio of the K of the IL-18 / IL-18BP interaction exhibited by the active form of the IL-18 polypeptide is at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, or at least about 50. D K interacting with IL-18 / IL-18Rαβ D The ratio of IL-18 / IL-18BP to IL-18 is at least about 2. In some embodiments, the active form of the IL-18 polypeptide exhibits a K of IL-18 / IL-18BP interaction of D K interacting with IL-18 / IL-18Rαβ D In some embodiments, the active form of the IL-18 polypeptide exhibits a K of IL-18 / IL-18BP interaction of at least about 5. D K interacting with IL-18 / IL-18Rαβ D In some embodiments, the active form of the IL-18 polypeptide exhibits a K of IL-18 / IL-18BP interaction of at least about 10. D K interacting with IL-18 / IL-18Rαβ DIn some embodiments, the active form of the IL-18 polypeptide exhibits a K of IL-18 / IL-18BP interaction of at least about 25. D K interacting with IL-18 / IL-18Rαβ D In some embodiments, the active form of the IL-18 polypeptide exhibits a K of IL-18 / IL-18BP interaction of at least about 30. D K interacting with IL-18 / IL-18Rαβ D In some embodiments, the active form of the IL-18 polypeptide exhibits a K of IL-18 / IL-18BP interaction of at least about 40. D K interacting with IL-18 / IL-18Rαβ D In some embodiments, the active form of the IL-18 polypeptide exhibits a K of IL-18 / IL-18BP interaction of at least about 45. D K interacting with IL-18 / IL-18Rαβ D The ratio is at least about 50.

[0238] Functional activity of activated forms of IL-18 polypeptides

[0239] In some embodiments, the active forms of the IL-18 polypeptides provided herein exhibit one or more activities associated with WT IL-18. In some embodiments, the active forms of the IL-18 polypeptides exhibit similar ability to signal through the IL-18 receptor (IL-18Rαβ), but lack the ability to be inhibited by IL-18BP or exhibit reduced ability to be inhibited by IL-18BP. In some embodiments, the ability of the active form of the IL-18 polypeptide to signal through IL-18Rαβ is only slightly reduced compared to WT IL-18.

[0240] In some embodiments, the active form of the IL-18 polypeptide modulates IFNγ production when in contact with a cell (e.g., an immune cell such as a NK cell). In some embodiments, the ability of the active form of the IL-18 polypeptide to modulate IFNγ production is measured at a half-maximal effective concentration (EC 50 ). In some embodiments, the EC of the ability of the active form of the Act-IL-18 polypeptide to induce IFNγ is 50 (nM) than the IL-18 polypeptide EC of SEQ ID NO:1 50 (nM) is less than 10-fold, less than 5-fold, or less than that. In some embodiments, the EC of the ability of the active form of the Act-IL-18 polypeptide to induce IFNγ is 50Compared with the EC of the IL-18 polypeptide of SEQ ID NO: 1 50 In some embodiments, the EC of the active form of the Act-IL-18 polypeptide for its ability to induce IFNγ is less than 10-fold higher. 50 Compared with the EC of the IL-18 polypeptide of SEQ ID NO: 1 50 In some embodiments, the EC of the active form of the IL-18 polypeptide for its ability to induce IFNγ is less than 5-fold higher. 50 Compared with the EC of the IL-18 polypeptide of SEQ ID NO: 1 50 In some embodiments, the EC of the active form of the IL-18 polypeptide for its ability to induce IFNγ is 50 Compared with the EC of the IL-18 polypeptide of SEQ ID NO: 1 50 (nM) is less than 10-fold, less than 8-fold, less than 6-fold, less than 5-fold, less than 4-fold, less than 3-fold, or less than 2-fold higher. In some embodiments, the EC of the ability of the active form of the IL-18 polypeptide to induce IFNγ is less than 10-fold, less than 8-fold, less than 6-fold, less than 5-fold, less than 4-fold, less than 3-fold, or less than 2-fold higher. 50 Measured by IFNγ induction cellular assay.

[0241] In some embodiments, the ability of the active form of the IL-18 polypeptide to induce IFNγ production is 50 In some embodiments, the EC of the ability of the active form of the IL-18 polypeptide to induce IFNγ production is less than about 100 nM, less than about 75 nM, less than about 50 nM, less than about 40 nM, less than about 30 nM, less than about 20 nM, less than about 15 nM, or less than about 10 nM. 50 Less than about 100 nM. In some embodiments, the ability of the active form of the IL-18 polypeptide to induce IFNγ production is 50 Less than about 50 nM. In some embodiments, the ability of the active form of the IL-18 polypeptide to induce IFNγ production is 50 Less than about 10 nM.

[0242] In some embodiments, the active form of IL-18 exhibits a reduced ability of its IFNγ inducing activity to be inhibited by IL-18BP compared to WT IL-18. In some embodiments, the active form of IL-18 exhibits a half-maximal inhibitory concentration (IC 50 ) than WT IL-18 inhibited by IL-18BP 50In some embodiments, the active form of IL-18 exhibits a half-maximal inhibitory concentration (IC) of IL-18BP. 50 ) than WT IL-18 inhibited by IL-18BP 50 In some embodiments, the active form of IL-18 exhibits a half-maximal inhibitory concentration (IC 50 ) than WT IL-18 inhibited by IL-18BP 50 In some embodiments, the active form of IL-18 exhibits a half-maximal inhibitory concentration (IC 50 ) than WT IL-18 inhibited by IL-18BP 50 At least about 1000 times higher.

[0243] In some embodiments, the active form of the IL-18 polypeptide exhibits a half-maximal inhibitory concentration (IC 50 ) and the half-maximal effective concentration (EC 50 )'s favorable ratio (IC 50 / EC 50 In some embodiments, the IC 50 / EC 50 In some embodiments, the IC 50 / EC 50 In some embodiments, the IC 18 is increased by at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, at least about 500-fold, at least about 600-fold, at least about 700-fold, at least about 800-fold, at least about 900-fold, or at least about 1000-fold compared to WT IL-18. 50 / EC 50 In some embodiments, the IC IL-18 is increased by at least about 10-fold compared to WT IL-18. 50 / EC 50 In some embodiments, the IC IL-18 is increased by at least about 100-fold compared to WT IL-18. 50 / EC 50In some embodiments, the IC of the active form of the Act-IL-18 polypeptide is at least about 500-fold greater. 50 / EC 50 The ratio is at least about 2, at least about 5, at least about 10, at least about 50, at least about 100, at least about 250, or at least about 500.

[0244] In some embodiments, the active form of the IL-18 polypeptide modulates IFNγ production, and wherein the active form of the Act-IL-18 polypeptide is directed against the EC of IFNγ. 50 (nM) is less than the EC of the IL-18 polypeptide of SEQ ID NO: 1 50 (nM). In some embodiments, the active form of the Act-IL-18 polypeptide is directed against the EC of IFNγ. 50 (nM) than the EC of the IL-18 polypeptide of SEQ ID NO: 1 50 In some embodiments, the active form of the Act-IL-18 polypeptide is directed against the EC of IFNγ. 50 (nM) than the EC of the IL-18 polypeptide of SEQ ID NO: 1 50 In some embodiments, the active form of the Act-IL-18 polypeptide is directed against the EC of IFNγ. 50 (nM) than the EC of the IL-18 polypeptide of SEQ ID NO: 1 50 (nM) is approximately 15 times smaller.

[0245] Relative activity of IL-18 activatable and active forms

[0246] In some embodiments, the activated form of the IL-18 polypeptide (e.g., after cleavage at the specific cleavage site) exhibits an enhanced activity associated with IL-18 compared to an Act-IL-18 polypeptide with an intact specific cleavage site. In some embodiments, the active form of the IL-18 polypeptide exhibits an activity that is at least 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, 200-fold, 500-fold, 1000-fold, 2000-fold, 5000-fold, 10000-fold, 15000-fold, or 20,000-fold greater than that of the Act-IL-18 polypeptide. Such activity may include inducing IFNγ production in cells (e.g., immune cells such as NK cells), activating signaling through the IL-18 receptor (e.g., in a reporter assay), or other in vitro or in vivo activity. In some embodiments, the activated form of the IL-18 polypeptide exhibits enhanced binding to the IL-18 receptor or a subunit thereof (e.g., the IL-18 receptor α subunit) compared to the Act-IL-18 polypeptide (e.g., having a K of at least 10-fold, 20-fold, 50-fold, or 100-fold lower).D ).

[0247] In some embodiments, the Act IL-18 polypeptide exhibits a half-maximal effective concentration (EC) of IL-18 receptor signaling activity greater than the activated form of the IL-18 polypeptide. 50 In some embodiments, the Act IL-18 polypeptide exhibits an EC of IL-18 receptor signaling activity that is at least 1,000-fold higher, 2,000-fold higher, 5,000-fold higher, 10,000-fold higher, 15,000-fold higher, or 20,000-fold higher than an activated form of the IL-18 polypeptide. 50 In some embodiments, the Act IL-18 polypeptide exhibits an EC of IL-18 receptor signaling activity that is at least 1,000-fold greater than that of an activated form of the IL-18 polypeptide. 50 In some embodiments, the Act IL-18 polypeptide exhibits an EC of IL-18 receptor signaling activity that is at least 5,000-fold greater than that of an activated form of the IL-18 polypeptide. 50 In some embodiments, the Act IL-18 polypeptide exhibits an EC of IL-18 receptor signaling activity that is at least 10,000-fold greater than that of an activated form of the IL-18 polypeptide. 50 In some embodiments, the ActIL-18 polypeptide exhibits an EC of IL-18 receptor signaling activity that is at least 20,000-fold greater than that of an activated form of the IL-18 polypeptide. 50 .

[0248] In some embodiments, the Act-IL-18 polypeptide exhibits only a modest decrease in activity compared to an activated form of the IL-18 polypeptide. In some embodiments, the Act-IL-18 polypeptide exhibits a half-maximal effective concentration (EC ) of IL-18 receptor signaling activity that is about 10 to about 100 times higher than an activated form of the IL-18 polypeptide. 50 In some embodiments, the ActIL-18 polypeptide exhibits an EC of IL-18 receptor signaling activity that is about 10-fold to about 50-fold higher than the activated form of the IL-18 polypeptide. 50 .

[0249] In some embodiments, the activated form of the IL-18 polypeptide has an activity comparable to that of the IL-18 polypeptide from which the Act-IL-18 polypeptide is derived. In some embodiments, the activated form of the IL-18 polypeptide exhibits a half-maximal effective concentration (EC 500) of IL-18 receptor signaling activity that is within about 10-fold of that of the IL-18 polypeptide. 50 ).

[0250] III. Pharmaceutical Compositions

[0251] In one aspect, described herein is a pharmaceutical composition comprising: an Act-IL-18 polypeptide as described herein; and a pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition comprises a plurality of Act-IL-18 polypeptides. In some embodiments, the pharmaceutical composition further comprises one or more excipients selected from carbohydrates, inorganic salts, antioxidants, surfactants, or buffers.

[0252] In some embodiments, the pharmaceutical composition further comprises carbohydrates. In certain embodiments, the carbohydrates are selected from the group consisting of fructose, maltose, galactose, glucose, D-mannose, sorbose, lactose, sucrose, trehalose, cellobiose, raffinose, melezitose, maltodextrin, dextran, starch, mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (glucitol), pyranosyl sorbitol, inositol, cyclodextrin and combinations thereof.

[0253] In some embodiments, the pharmaceutical composition comprises an inorganic salt. In certain embodiments, the inorganic salt is selected from the group consisting of sodium chloride, potassium chloride, magnesium chloride, calcium chloride, sodium phosphate, potassium phosphate, sodium sulfate, or a combination thereof.

[0254] In certain embodiments, the pharmaceutical composition comprises an antioxidant. In certain embodiments, the antioxidant is selected from the group consisting of ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, potassium metabisulfite, propyl gallate, sodium metabisulfite, sodium thiosulfate, vitamin E, 3,4-dihydroxybenzoic acid, and combinations thereof.

[0255] In certain embodiments, the pharmaceutical composition comprises a surfactant. In certain embodiments, the surfactant is selected from the group consisting of polysorbates, sorbitan esters, lipids, phospholipids, phosphatidylethanolamines, fatty acids, fatty acid esters, steroids, EDTA, zinc, and combinations thereof.

[0256] In certain embodiments, the pharmaceutical composition comprises a buffer. In certain embodiments, the buffer is selected from the group consisting of citric acid, sodium phosphate, potassium phosphate, acetic acid, ethanolamine, histidine, amino acids, tartaric acid, succinic acid, fumaric acid, lactic acid, Tris, HEPES, CHAPS, or a combination thereof.

[0257] In some embodiments, the pharmaceutical composition is formulated for parenteral or enteral administration. In some embodiments, the pharmaceutical composition is formulated for intravenous or subcutaneous administration. In some embodiments, the pharmaceutical composition is in lyophilized form.

[0258] In one aspect, a liquid or lyophilized composition comprising the Act-IL-18 polypeptide is described herein. In some embodiments, the Act-IL-18 polypeptide is a lyophilized powder. In some embodiments, the lyophilized powder is resuspended in a buffer solution. In some embodiments, the buffer solution comprises a buffer, a sugar, a salt, a surfactant, or any combination thereof. In some embodiments, the buffer solution comprises a phosphate. In some embodiments, the phosphate is sodium Na2HPO4. In some embodiments, the salt is sodium chloride. In some embodiments, the buffer solution comprises phosphate-buffered saline. In some embodiments, the buffer solution comprises mannitol. In some embodiments, the lyophilized powder is suspended in a solution comprising a phosphate-buffered saline solution (pH 7.4) and 50 mg / mL mannitol. In some embodiments, the pharmaceutical composition is a lyophilized composition that is reconstituted shortly before being administered to a subject.

[0259] The Act-IL-18 polypeptides described herein can be in various dosage forms. In some embodiments, the Act-IL-18 polypeptide is administered as a lyophilized powder. In some embodiments, the Act-IL-18 polypeptide is administered as a suspension. In some embodiments, the Act-IL-18 polypeptide is administered as a solution. In some embodiments, the Act-IL-18 polypeptide is administered as an injectable solution. In some embodiments, the Act-IL-18 polypeptide is administered as an intravenous (IV) solution.

[0260] IV. Host Cells

[0261] In one aspect, described herein is a host cell that expresses an Act-IL-18 polypeptide.

[0262] In one aspect, described herein is a method of producing an Act-IL-18 polypeptide, wherein the method comprises expressing the Act-IL-18 polypeptide in a host cell.

[0263] In some embodiments, the host cell is a prokaryotic cell or a eukaryotic cell. In some embodiments, the host cell is a mammalian cell, an avian cell, or an insect cell. In some embodiments, the host cell is a mammalian cell, an avian cell, a fungal cell, or an insect cell. In some embodiments, the host cell is a CHO cell, a COS cell, or a yeast cell.

[0264] V. Treatment Methods

[0265] In one aspect, described herein is a method of treating cancer in a subject in need thereof, the method comprising: administering to the subject an effective amount of an Act-IL-18 polypeptide or a pharmaceutical composition as described herein.

[0266] In another aspect, described herein is an Act-IL-18 polypeptide as provided herein for use in treating cancer in a subject in need thereof. In another aspect, described herein is an Act-IL-18 polypeptide as provided herein for use in the manufacture of a medicament for treating cancer in a subject in need thereof.

[0267] In some embodiments, the cancer is a solid cancer. In some embodiments, wherein the solid cancer is adrenal cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, carcinoid, cervical cancer, colorectal cancer, esophageal cancer, eye cancer, gallbladder cancer, gastrointestinal stromal tumors, germ cell cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, neuroendocrine cancer, oral cancer, oropharyngeal cancer, ovarian cancer, pancreatic cancer, pediatric cancer, penile cancer, pituitary cancer, prostate cancer, skin cancer, soft tissue cancer, spinal cord cancer, stomach cancer, testicular cancer, thymus cancer, thyroid cancer, ureter cancer, uterine cancer, vaginal cancer or vulvar cancer.

[0268] In some embodiments, the cancer is a blood cancer. In some embodiments, the cancer is a blood cancer. In some embodiments, the blood cancer is leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, AIDS-related lymphoma, multiple myeloma, plasmacytoma, post-transplant lymphoproliferative disorder, or Waldenstrom's macroglobulinemia.

[0269] In some embodiments, a single dose of an effective amount of the Act-IL-18 polypeptide is administered, including additional embodiments wherein (i) the Act-IL-18 polypeptide is administered once a day; or (ii) the Act-IL-18 polypeptide is administered to a subject multiple times over the span of a day. In some embodiments, the Act-IL-18 polypeptide is administered once a day, once every other day, 3 times a week, once a week, twice a week, once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, once every 6 weeks, once every 12 weeks, once every 3 days, once every 4 days, once every 5 days, once every 6 days, twice a week, 3 times a week, 4 times a week, 5 times a week, 6 times a week, once a month, twice a month, 3 times a month, 4 times a month, once every 2 months, once every 3 months, once every 4 months, once every 5 months, or once every 6 months.

[0270] In some embodiments, the method further comprises reconstituting a lyophilized form of the Act-IL-18 polypeptide or pharmaceutical composition. In some embodiments, the Act-IL-18 polypeptide or pharmaceutical composition is reconstituted prior to administration. In some embodiments, the composition is reconstituted immediately prior to administration, up to about 5 minutes prior to administration, up to about 20 minutes prior to administration, up to about 40 minutes prior to administration, up to 1 hour prior to administration, or up to about 4 hours prior to administration.

[0271] Exemplary IL-18 sequences

[0272] The sequences provided in the following table represent exemplary IL-18 polypeptides, which can be a portion of an Act-IL-18 polypeptide as provided herein. In some embodiments, the IL-18 polypeptide of the Act-IL-18 polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence shown in any one of SEQ ID Nos: 1-67. In some embodiments, the IL-18 polypeptide of the Act-IL-18 polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence shown in any one of SEQ ID Nos: 79-83. In some embodiments, the IL-18 polypeptide of the Act-IL-18 polypeptide comprises an amino acid sequence as shown in any one of SEQ ID Nos: 1-67. In some embodiments, the Act-IL-18 polypeptide comprises an amino acid sequence as shown in SEQ ID NO: 30. In some embodiments, the IL-18 polypeptide of the Act-IL-18 polypeptide comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 79-83. In some embodiments, the IL-18 polypeptide of the Act-IL-18 polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 79. In some embodiments, the IL-18 polypeptide of the Act-IL-18 polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 80. In some embodiments, the IL-18 polypeptide of the Act-IL-18 polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 81. In some embodiments, the IL-18 polypeptide of the Act-IL-18 polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 82. In some embodiments, the IL-18 polypeptide of the Act-IL-18 polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 83.

[0273] Table 3 - IL-18 polypeptides

[0274]

[0275]

[0276]

[0277]

[0278]

[0279]

[0280]

[0281]

[0282]

[0283] Additional Exemplary IL-18 Constructs

[0284] Also provided herein are IL-18 polypeptides comprising the modifications to SEQ ID NO: 1 listed in the table below, each modification being assigned a composition ID. In some embodiments, the IL-18 polypeptide of the Act-IL-18 polypeptide comprises the amino acid substitution group set forth in any of the constructs depicted below. In the constructs depicted below, each substitution is listed using SEQ ID NO: 1 as a reference sequence. In some embodiments, the IL-18 polypeptide of the Act-IL-18 polypeptide comprises only the substitutions shown in the following constructs relative to SEQ ID NO: 1 (i.e., the IL-18 polypeptide has only the indicated substitution group, and the remaining residues are the residues shown in SEQ ID NO: 1).

[0285] Table 4 - Additional IL-18 constructs

[0286]

[0287]

[0288] Exemplary ACT-IL-18 sequences and controls

[0289]

[0290]

[0291]

[0292]

[0293] Although the present disclosure and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the disclosure as defined by the appended claims.

[0294] The present disclosure is further illustrated in the following examples, which are provided for illustrative purposes only and are not intended to limit the present disclosure in any way.

[0295] Example

[0296] Example 1A - Recombinant Act-IL18 Expression and Purification

[0297] The recombinant Act-IL-18 variants provided herein can be prepared according to the protocol provided below.

[0298] Soluble His-SUMO-IL18 variant

[0299] E. coli BL21 (DE3) containing plasmids encoding N-His-SUMO-tagged IL-18 variant fusions was inoculated into 3 L LB medium and induced with 0.4 mM IPTG at 30°C for 6 hours. The cells were pelleted and sonicated in a lysis buffer (PBS, pH 7.4). The soluble protein was purified via Ni-NTA beads 6FF (wash 1: PBS, 20 mM imidazole, pH 7.4; wash 2: PBS, 50 mM imidazole, pH 7.4; elution: PBS, 500 mM imidazole, pH 7.4).

[0300] The fractions containing protein are pooled, dialyzed into PBS at pH 7.4, and subsequently SUMO digested. The protein is then purified in two steps using Ni-NTA beads (continuous flow through sample) and gel filtration. The fractions containing protein are pooled, and QC is performed using analytical techniques such as SDS-PAGE and analytical SEC.

[0301] Insoluble His-SUMO-IL18 variant

[0302] E. coli BL21 (DE3) containing plasmids encoding N-His-SUMO-tagged IL-18 variant fusions was inoculated into 10 L LB medium and induced with 0.4 mM IPTG at 30°C for 6 hours. The cells were pelleted and sonicated in a lysis buffer (PBS, 8 M urea, pH 7.4). The protein was purified via Ni-NTA beads 6FF (wash 1: PBS, 8 M urea, 20 mM imidazole, pH 7.4; wash 2: PBS, 8 M urea, 50 mM imidazole, pH 7.4; elution: PBS, 8 M urea, 500 mM imidazole, pH 7.4).

[0303] The fractions containing protein were pooled, dialyzed into PBS at pH 7.4, and subsequently digested with SUMO. The protein was then purified using Ni-NTA beads (using PBS, 8M urea, pH 7.4 for balancing the column; using PBS, 8M urea, pH 7.4 for washing; using PBS, 8M urea, pH 7.4 for elution). The fractions containing protein were pooled, dialyzed into PBS pH 7.4, and QC was performed using analytical techniques such as SDS-PAGE and analytical SEC.

[0304] Insoluble untagged IL18 variant

[0305] E. coli BL21 (DE3) containing plasmid (which encodes mIL-18) was inoculated into 2L LB medium and induced with 0.4mM IPTG at 30°C for 6 hours. The cells were pelleted and sonicated in a lysis buffer (110mM Tris, 1.1M guanidine HCl, 5mM DTT, pH 8.9). The protein was purified via Q Sepharose FF (equilibrium buffer 20mM MES, pH 7.0, eluted using an increasing gradient from 0M to 1M NaCl).

[0306] Bicistronic system

[0307] The single colony of the Escherichia coli BL21 containing plasmid (e.g., SEQ ID NO:59) was used as an inoculum of 10mL LB containing 25 μg / ml kanamycin sulfate, and incubated overnight at 37°C and 200rpm. 1mL pre-culture was used to inoculate 1L of the auto-induction terrific culture medium containing 100 μg / mL kanamycin sulfate. The culture was incubated at 37°C and 110rpm for 4h, and then transferred to 15°C for another 15h. The cells were resuspended in 10-15mL lysis buffer (100mM HEPES, 1mM EDTA, 5mM DTT, 20 μg / mL lysozyme, 0.1mg / mL DNA enzyme I, 1mM PMSF, pH 7.5), and gently vibrated for 1h at 4°C. The cells were then sonicated, and the soluble protein fraction was obtained by centrifugation (16'000 × g, 30min, 4°C) and filtration (0.2 μm membrane).

[0308] The supernatant was adjusted to about pH 7 and loaded onto a tandem column system (2×SP CIEX+1×HiPrep DEAE FF 16 / 10, all from cytiva) using a 50 mL superloop (less than 30 mL of lysate was loaded per run). The system was run with wash buffer (25 mM HEPES, 1 mM EDTA, 5 mM DTT, pH 7.0), and fractions containing protein (second major peak) were collected and pooled.

[0309] The series column is divided into their respective types.DEAE column is eluted with step gradient using buffer E1 and E2 (respectively 25mM Bus-Tris-propane HCl, pH 9.5 and 25mM Bis-Tris-propane HCl, 1M NaCl, pH 9.5).First, 100% E1 runs 8 CV, followed by the E2 gradient from 0% to 12% in 5 CV, and then it is maintained at 12%, and then continues 10 CV.After this, it is the E2 gradient from 12% to 40% in 5 CV, and it is maintained at 40%, and then continues 5 CV.Collect the fraction (second main peak) containing protein and gather with previous fraction.Wash SP post and discard with the same method, because in this elution, will not find protein.

[0310] The pooled samples were adjusted to pH 9.5 and loaded on Mono Q (small scale) or Hitrap Q (large scale) columns. The buffer used was E2 and E3 (25 mM Bis-Tris propane HCl, 1.5 M ammonium sulfate, pH 9.5). For 15 CV, the step elution gradient started from 8% E3, increased to 16% E3 in 5 CVs, and increased to 50% E3 in 3 CVs. The fraction containing the protein was found in the second main peak.

[0311] Fractions containing the target protein were pooled and concentrated by diafiltration (10 kDa MWCO, less than 3500 x g, 4°C). The concentrated sample was loaded on a Superdex 75 equilibrated with buffer (20 mM potassium phosphate, 150 mM KCl, 1 mM DTT, pH 6.0). Fractions containing the target protein were collected, pooled and concentrated.

[0312] Example 1B - Expression and purification of selected activatable IL-18 polypeptides

[0313] Activatable IL-18 candidates linked to an N-terminal propeptide were prepared according to the methods provided below.

[0314] 1.1-Expression of activatable IL-18 candidates

[0315] The IL-18 candidate was generated as an N-terminal fusion of N-His-SUMO-IL18. The gene was synthesized and cloned into a plasmid. The plasmid was transformed into E. coli BL21 (DE3). Expression was performed in a shake flask with TB medium. The cells were grown at 37°C until the OD600 reached approximately 1.2, then induced with 0.1 mM IPTG and cultured at 18°C ​​for another 20 hours. The cells were harvested by centrifugation.

[0316] 1.2-Purification of activatable IL-18 candidates

[0317] 1.2.1-Cell lysis

[0318] The cells were resuspended in lysis buffer (20 mM Tris / HCl, pH 8.0, 0.15 M NaCl, 10 mM imidazole, 1 tablet of EDTA-free complete protease inhibitor (Roche, COEDTA F-RO) per liter of production) at 100 mL buffer / L culture and disrupted twice with a homogenizer at 1000 bar. The lysate was cleared of debris by centrifugation 2×45 minutes at 40,000 g, changing flasks during centrifugation, and then filtering through a 0.22 μm filter.

[0319] 1.2.2-Affinity purification and endotoxin removal

[0320] The lysate was loaded onto a Ni NTA resin (Cytiva, 17524802) pre-equilibrated with 20mM Tris / HCl, pH 8.0, 0.15M NaCl, 10mM imidazole at 5 mL / min and washed with the same buffer for 5CV. In order to remove endotoxin, the column was washed with 20mM Tris / HCl, pH 8.0, 0.15M NaCl, 10mM imidazole, 0.1% Triton X-114 at 10 mL / min for 30CV. The column was washed with 20mM Tris / HCl, pH 8.0, 0.15M NaCl, 10mM imidazole at 5 mL / min for 5CV, and the target protein was eluted by a linear increase in imidazole concentration. The column was then regenerated by 0.5M NaOH.

[0321] 1.2.3-SUMO digestion and dialysis

[0322] To cleave the SUMO tag, SUMO protease was added to the elution pool at a w / w ratio of 1:250 (protein:SUMO enzyme) and incubated for 18 hours at 4° C. In parallel, the protein was dialyzed (20 mM Tris, pH 8.0, 150 mM NaCl) to reduce the imidazole concentration.

[0323] 1.2.4-Purification by reverse IMAC

[0324] To remove the cleaved tag and SUMO protease, the digested protein was passed through a Ni NTA resin column pre-equilibrated with 20 mM Tris / HCl, pH 8.0, 0.15 M NaCl, 10 mM imidazole at 5 mL / min. The flow-through was collected.

[0325] The flow-through was concentrated to 2.6 mg / mL and the buffer was exchanged to 20 mM HEPES, 150 mM NaCl, 0.5 mM TCEP, 10% glycerol, pH 7.5 or PBS, 10% glycerol, pH 7.4. The protein was stored at -70°C until further quality control.

[0326] Example 1C

[0327] Act-IL-18 polypeptides are prepared using mammalian expression systems using methods well known in the art.

[0328] Example 2 - Cleavage of Activatable IL-18 Polypeptides

[0329] Cleavage of activatable IL-18 polypeptides was performed according to the following protocol: IL-18 candidates (activatable or non-cleavable controls) were incubated with MMP2 (SIGMA, PF023), MMP7 (SIGMA, CC1059) or MMP9 (SIGMA, PF024) diluted in MMP buffer MMP (25mM TRIS, 10mM CaCl2, 0.05% Brij25, pH 7.5), with a final concentration of 1ug / ml for MMP2 and MMP9 and 10ug / ml for MMP7. Protein controls without enzymes were incubated under the same conditions. After 20 hours of incubation, samples were collected for SDS gel analysis.

[0330] For candidates presenting a C-terminal masking domain, a further washing step was performed by nickel beads to remove cleaved, histidine-tagged masking domains and uncleaved protein. Briefly, the protein and enzyme solution was incubated with excess nickel beads (at least 10 uL dry beads per expected 40 ug protein) for 30 minutes under shaking conditions. The flow-through was collected and bound residues were eluted from the beads by incubation with 20 mM TRIS, 150 mM NaCl, 500 mM imidazole, pH 8.

[0331] Fig.14A Panels 4 to 5 show SDS-PAGE gels from cleavage experiments performed on the indicated IL-18 molecules. Fig.14A The digestion results of N-terminal masking candidates by MMP2, MMP7 and MMP9 are shown, where protease treated samples are indicated by (+) and untreated samples are indicated by (-). Variant C127 showed efficient cleavage by each enzyme, C185 showed moderate cleavage by each enzyme, and C187 showed moderate cleavage by MMP2 and MMP7, but moderate cleavage by MMP9, while basic IL-18 C086 and non-cleavable control C190 remained intact under all conditions. Fig. 14BThe digestion results of C-terminal masking candidates by MMP2, MMP7 and MMP9 (not purified) are shown, where protease-treated samples are indicated by (+) and untreated samples are indicated by (-). Variant C136 showed no cleavage by any enzyme, C137 showed no cleavage by any enzyme, C172 showed efficient cleavage by all enzymes, C173 showed some cleavage by MMP7, C189 showed efficient cleavage by all enzymes, and C191 showed moderate cleavage by MMP2, efficient cleavage by MMP7, and no cleavage or minimal cleavage by MMP9. Fig. 14C C-terminal masking candidates are shown (with Fig. 14B Digestion results of the nickel purification effluent (FT) and eluate (E) of the same sample).

[0332] Example 3A - HEK-Blue IL18R reporter assay

[0333] Binding of IL-18 variants to IL-18Rαβ and subsequent downstream signaling was determined using an IL-18Rαβ-positive HEK-Blue reporter cell line. The general protocol is outlined below.

[0334] 5 × 104 cells HEK-Blue IL18R reporter cells (InvivoGen, #hkb-hmil18) were inoculated into each well of a 96-well plate and stimulated with 0-100nM IL-18 polypeptide variants at 37°C and 5% CO2. After incubation for 20 hours, 20 μL of cell culture supernatant was then taken out from each well and mixed with 180 μL of QUANTI-Blue culture medium in a 96-well plate and incubated for 1 hour at 37°C and 5% CO2. The absorbance signal at 620 nm was then measured on an Enspire plate reader, with excitation and emission wavelengths of 680 nm and 615 nm, respectively. The half-maximum effective dose (EC50) was calculated using GraphPad PRISM software based on variable slope and four-parameter analysis.

[0335] Compared to WT IL-18 or IL-18 polypeptides without artificial terminal parts, Act-IL-18 polypeptides provided herein exhibit reduced or abolished ability to stimulate IFNγ binding. After cleavage, the ability to stimulate IFNγ is restored, but may be altered relative to WT IL-18.

[0336] Example 3B - HEK-Blue IL18R reporter assay - Results

[0337] The above-described HEK-Blue IL-18R reporter assay was performed on activatable IL-18 polypeptides and control IL-18 polypeptides before and after treatment with the indicated MMPs. The activity in the HEK-Blue IL18R assay is provided in the table below.

[0338]

[0339] Example 3C

[0340] The HEK-Blue IL-18R reporter assay described above is performed on additional IL-18 polypeptides that can be incorporated into the Act-IL-18 polypeptides as provided herein. It is expected that the IL-18 polypeptides provided below will behave similarly to C086 (SEQ ID NO: 30) when converted to the Act-IL-18 polypeptides provided elsewhere herein.

[0341]

[0342]

[0343]

[0344] Example 4 - Stability Assessment of IL-18

[0345] Nano differential scanning fluorescence (nanoDSF) was used to evaluate the stability of activatable IL-18 polypeptides and control IL-18 polypeptides. Compared with C086, activatable IL-18 polypeptide constructs linked to the propeptide or IL-18 receptor D3 subunit showed enhanced stability. In contrast, IL-18 polypeptides with a short extension peptide linked to the N-terminus showed lower stability.

[0346]

[0347] In some cases, IL-18 polypeptides were treated with MMP or MMP buffer without MMP according to the following general protocol: 100 uL of approximately 1 mg / mL of the indicated IL-18 sample was mixed with 100 uL of 2 ug / mL MMP-2 in MMP assay buffer (25 mM TRIS, 10 mM CaCl2, 0.05% Brij 25, pH 7.5). The samples were incubated at 24° C. with shaking for 16 hours.

[0348]

[0349] Example 5A-Conjugation of Act-IL-18 polypeptide

[0350] As provided herein, Act-IL-18 polypeptides are conjugated to PEG functional groups. In some cases, PEG is attached via a bifunctional linker that is first attached to a desired residue of the Act-IL-18 polypeptide (e.g., E85C or another suitable naturally occurring cysteine ​​such as C68) or a cysteine ​​residue that has been incorporated at a desired site (such as residues 86 or 98). After attachment to the IL-18 polypeptide, the second functional group of the bifunctional linker is used to attach the PEG moiety. An exemplary schematic diagram of such an approach is shown in Figure 6 In some cases, it is not necessary to Figure 6 The bifunctional linker shown is not shown because the IL-18 polypeptide already contains the desired conjugation handle for attachment of PEG or other groups. Exemplary schemes of recombinant IL-18 variants provided herein are described below.

[0351] Conjugation - Recombinant IL-18 was stored at a concentration of 2.4 mg / mL in potassium phosphate buffer (pH 7.0) containing 50 mM KCl and 1 mM DTT at -80°C. The sample was thawed on ice to produce a clear solution. The protein solution was diluted in PBS, pH 7.4. A clear solution with a concentration of approximately 0.4 mg / mL was obtained.

[0352] The protein solution was dialyzed against PBS, pH 7.4 (twice for 600 mL, for 2 hours, and once for 800 mL, for 18 hours). After dialysis, a clear solution with no signs of precipitation was obtained. The protein concentration was obtained using UV absorbance at 280 nm and by BCA protein assay.

[0353] Prepare a stock solution of the bifunctional probe (bromoacetamide-PEG5-azide, CAS: 1415800-37-1) at a concentration of 20 mM in water. Mix 500 μL of the protein solution with 25 μL of the probe solution. Adjust the pH to 7.5 and react at 20°C for 3 hours.

[0354] The progress of the synthesis was monitored by reverse phase HPLC at 40 °C with a flow rate of 1 mL / min in an Aeris WIDEPORE C18 A gradient of 5 to 30% (2.5 min) and 30 to 75% (7.5 min) CH3CN and 0.1% TFA (v / v) was used on a column (3.6 μm, 150 x 4.6 mm) and monitored by MALDI-TOF MS.

[0355] Purification - In some cases, ion exchange chromatography was used to purify the conjugated protein. To remove excess probe, the reaction mixture (volume of approximately 500 μL) was passed through a Hi-Trap-G-FF-1 mL column using 25 mM Tris (pH 7.4) as a buffer. The column was eluted using a linear gradient of 0-0.35 M NaCl in the same buffer. Fractions containing the target protein were collected, the buffer was exchanged (25 mM Tris, pH 7.4, 75 mM NaCl, 5% glycerol) and concentrated to 0.4 mg / mL. The concentration of the purified protein was determined by UV absorbance at 280 nm and by BCA protein assay. The protein solution was stored at -80 °C

[0356] Characterization - The purity and identity of commercially sourced recombinant and conjugated proteins were confirmed by analytical SEC, HPLC, and MALDI-TOF MS.

[0357] The Act-IL-18 polypeptide may then be further conjugated to additional groups, such as a polymer or another polypeptide.

[0358] Example 5B-PEGylation of Act-IL-18 polypeptide

[0359] In the manner described in Example 5A and Figure 7 After conjugation with the bifunctional linker shown, the Act-IL-18 polypeptide can be covalently linked to the PEG group. An exemplary schematic diagram of this method is shown in Figure 7 An exemplary scheme for the conjugation reaction between PEG and an appropriately activated IL-18 polypeptide is provided below. In addition, the following scheme can be used to directly covalently link the desired PEG group to an Act-IL-18 polypeptide incorporating a conjugation handle during the preparation of the Act-IL-18 polypeptide (e.g., during the synthesis of a synthetic IL-18 polypeptide). An exemplary schematic diagram of such a method is shown in Figure 3 The resulting polymer-linked Act-IL-18 polypeptide is depicted in Figure 4 Its half-life is expected to be prolonged.

[0360] Conjugation - Recombinant Act-IL-18 polypeptides comprising SEQ ID NO: 59 with artificial terminal moieties as provided herein were stored at -80°C in PBS (pH 7.4) containing 75 mM NaCl and 5% (v / v) glycerol. Prior to the PEGylation reaction, the samples were thawed on ice to produce a clear solution. 200 μL of the protein solution (0.4 mg / mL) was mixed with 2.0 mg of DBCO-polyethylene glycol polymer. It was allowed to react overnight at 20°C.

[0361] The results were analyzed by reverse phase HPLC (Aeris WIDEPORE C4 The progress of the synthesis was monitored by MALDI-TOF MS on a column (3.6 μm, 150×4.6 mm) at a flow rate of 1 mL / min at 40° C. using gradients of 5% to 30% (2.5 min) and 30% to 75% (7.5 min) CH 3 CN containing 0.1% TFA (v / v).

[0362] Purification - To remove excess PEG, the reaction mixture was diluted with Tris buffer (25mM, pH 7.4) and 25mM Tris (pH 7.4) was used as a buffer to flow through the Hi-Trap-Q-FF column. A linear gradient of 0-0.35M NaCl was used to elute the column in the same buffer. The fractions containing the target protein were collected, the buffer was exchanged (25mM Tris, pH 7.4, 75mM NaCl, 5% glycerol) and concentrated to 0.04mg / mL. The concentration of the purified protein was determined by BCA protein assay. The protein solution was stored at -80°C.

[0363] Characterization - The purity and identity of the conjugated protein were confirmed by HPLC and MALDI-TOF MS.

[0364] Using a similar approach, the Act-IL-18 polypeptide can also be linked to another polypeptide, such as a suitable activating antibody.

[0365] Example 6 - Characterization of Act-IL-18 polypeptide

[0366] The Act-IL-18 polypeptides provided herein were subjected to a series of analytical experiments to characterize the compositions. The Act-IL-18 polypeptides were analyzed by HPLC to determine the homogeneity of the compositions. The Act-IL-18 polypeptide compositions were also analyzed by MALDI-MS to determine the MW and molecular weight distribution of the compositions. The Act-IL-18 polypeptide compositions were further analyzed by circular dichroism to compare the folding of the Act-IL-18 polypeptide compositions compared to wild-type IL-18.

[0367] Example 7 - Formulation of Act-IL-18 polypeptide

[0368] The lyophilized Act-IL-18 polypeptide is suspended in a solution containing 10-50 mM histidine buffer, 5%-10% trehalose, and 0.02% Tween. The lyophilized Act-IL-18 polypeptide can also be resuspended in other suitable or appropriate buffers such as PBS (pH 7.4) containing mannitol (e.g., 50 mg / mL) and Tween (e.g., 0.02%).

[0369] Example 8 - IL-18 SPR Measurement

[0370] The interaction of wild-type and Act-IL-18 polypeptides with human IL-18 receptor subunits was measured using surface plasmon resonance (SPR) technology. Anti-human IgG antibodies were bound to a CM5 chip by amine coupling to capture 6 μg / mL Fc-fused human IL-18Rα, 6 μg / mL Fc-fused human IL-18Rβ, or 2 μg / mL Fc-fused human IL-18BP isoform a (IL-18BPa) for 30 min before capture. In other settings, 6 μg / mL of α and β IL-18 receptors were mixed and pre-incubated for 30 min before capturing the α / β heterodimeric IL-18 receptor.

[0371] The kinetic binding of IL-18 analyte was measured with a Biacore 8K instrument with two-fold serial dilutions starting from 1 μM down to 0.98 nM. After each analyte concentration, the surface was regenerated as an amine-coupled anti-IgG antibody. In order to measure the association of the protein with the receptor, the sample was injected at a flow rate of 50 μL / min for 60 s, followed by 300 s of separate buffer to detect dissociation. The running buffer used was 1xPBS containing 0.05% Tween20. The relative response units (RU, Y axis) were plotted against time (s, X axis), and the binding of monomeric receptors and to IL-18BP were analyzed with a kinetic 1: 1 binding model. The kinetic heterogeneous ligand fitting model was applied to α / β heterodimer binding.

[0372] Compared to WT IL-18 or IL-18 polypeptides without an artificial terminal portion, the Act-IL-18 polypeptides provided herein exhibit reduced or abolished binding to IL-18Rαβ, IL-Rα and / or IL-18Rβ. After cleavage, binding to these IL-18 receptor proteins is restored, but may be altered relative to WT IL-18.

[0373] Example 9 - IL-18BP binding alphaLISA assay

[0374] The Human IL-18BP AlphaLISA Assay Kit was used to determine the binding affinity of each IL-18 variant to IL-18BP, which detects the presence of the free form of IL-18BP.

[0375] Sixteen three-fold serial dilutions of IL-18 analyte were prepared in the presence of 5 ng / mL His-tagged human IL-18BP in aMEM medium supplemented with 20% FCS, Glutamax and 25 μM β-mercaptoethanol. The final IL-18 analyte concentration ranged from 2778 nM to 0.2 pM.

[0376] After incubation at room temperature for 1 h, human IFNγ The assay kit measures free IL-18BP levels. In a 384-well OPTIplate, 5 μL of 5X anti-IL-18BP receptor beads were added to a 7.5 μL IL-18 / IL-18BP mixture. After incubation at room temperature with shaking for 30 min, 5 μL of biotinylated anti-IL-18BP antibody was added to each well. The plate was then incubated at room temperature for 1 h. Under subdued light, 12.5 μL of 2X streptavidin (SA) donor beads were pipetted into each well, and the wells were incubated at room temperature with shaking for 30 min. The AlphaLisa signal was then measured on the Enspire plate reader, with excitation and emission wavelengths of 680 nm and 615 nm, respectively. The dissociation constant (KD) was calculated using GraphPad PRISM software based on variable slope and four-parameter analysis.

[0377] The Act-IL-18 polypeptides provided herein can exhibit reduced or abolished binding to IL-18BP when attached to an artificial terminal moiety.

[0378] The above experiments were also performed on IL-18 polypeptides that can be incorporated into Act-IL-18 polypeptides as provided herein to assess the ability to bind to IL-18BP.

[0379]

[0380]

[0381] Example 10 - IFNγ-induced cell assay

[0382] The IL-18 polypeptides provided herein were evaluated for induction of IL-18 in a cell-based assay according to the following protocol. ability.

[0383] The NK cell line NK-92 ( CRL-2407TM) were cultured in aMEM medium supplemented with 20% FCS, Glutamax, 25 μM β-mercaptoethanol and 100 IU / mL recombinant human IL-2.

[0384] On the day of the experiment, cells were harvested and washed with aMEM medium without IL-2 and containing 1 ng / mL recombinant human IL-12. After counting, cells were seeded in 384-well titration plates at 100,000 cells / well and incubated at 37°C / 5% CO2. 16 4-fold serial dilutions of IL-18 analyte were prepared in aMEM medium, and 1 ng / mL of IL-12 was added to NK-92 cells. The final IL-18 analyte concentration ranged from 56 nM to 5×10-5 pM.

[0385] After incubating the cells at 37°C / 5% CO2 for 16-20 h, 5 μL of the supernatant was carefully transferred to a 384-well OptiPlate. The assay kit measures IFNγ levels. Briefly, 10 μL of 2.5X AlphaLISA anti-IFNγ receptor beads and a biotinylated anti-IFNγ antibody mixture were added to 5 μL of NK-92 supernatant. The mixture was incubated at room temperature with shaking for 1 hour. Under low light, 2.5 μL of 2X streptavidin (SA) donor beads were pipetted into each well, and the wells were incubated at room temperature with shaking for 30 min. The AlphaLISA signal was then measured on an EnSpireTM plate reader, with excitation and emission wavelengths of 680 nm and 615 nm, respectively. The half-maximal effective concentration (EC50) was calculated using GraphPad PRISM software based on variable slope and four-parameter analysis.

[0386] Compared to WT IL-18 or IL-18 polypeptides without artificial terminal parts, Act-IL-18 polypeptides provided herein exhibit reduced or abolished ability to stimulate IFNγ binding. After cleavage, the ability to stimulate IFNγ is restored, but may be altered relative to WT IL-18.

[0387] Example 11 - IL-18 binding protein inhibition cell assay

[0388] The NK cell line NK-92 ( CRL-2407TM) were cultured in aMEM medium supplemented with 20% FCS-Glutamax, 25 μM β-mercaptoethanol and 100 IU / mL recombinant human IL-2.

[0389] On the day of the experiment, cells were harvested and washed with aMEM medium containing no IL-2 and 1 ng / mL recombinant human IL-12. After counting, cells were seeded in 384-well titration plates at 100,000 cells / well and incubated at 37°C / 5% CO2. 16 2-fold serial dilutions of Fc-fused human IL-18 binding protein isoforms (IL-18BPa) were prepared in aMEM medium. 1 ng / mL IL-12 containing 2 nM of each Act-IL-18 polypeptide variant was added to NK-92 cells. The final IL-18 analyte concentration was 1 nM, and the final IL-18BPa concentration ranged from 566 nM to 17 pM.

[0390] After the cells were incubated at 37°C / 5% CO2 for 16-20h, 5 μL of supernatant was carefully transferred to 384 microwell OptiPlate. Human IFNγAlphaLISA assay kit was used to measure IFNγ levels. Briefly, 10 μL of 2.5XAlphaLISA anti-IFNγ receptor beads and biotinylated anti-IFNγ antibody mixture were added to 5 μL of NK-92 supernatant. The mixture was incubated at room temperature with shaking for 1h. Under low light, 2.5 μL of 2X SA donor beads were moved into each well and incubated at room temperature with shaking for 30min. AlphaLISA signals were then measured on an EnSpireTM plate reader, with excitation and emission wavelengths of 680nm and 615nm, respectively. GraphPad PRISM software was used to calculate half-maximum inhibitory concentrations (IC50) based on variable slopes and four-parameter analysis.

[0391] The Act-IL-18 variants of the present disclosure are active and able to induce IFNγ secretion in vitro after cleavage of the artificial terminal moiety, but are shown to have reduced or no ability to induce IFNγ in the absence of cleavage.

[0392] The modified IL-18 polypeptides were subjected to the experiments described in Examples 10 and 11 to evaluate their activity and their suitability for conversion into Act-IL-18 polypeptides.

[0393]

[0394]

[0395]

[0396] Example 12 - Pharmacokinetic and pharmacodynamic properties of Act-IL-18 polypeptide variants

[0397] The pharmacokinetic (PK) and pharmacodynamic (PD) properties of selected IL-18 polypeptide variants were measured. Three C57BL / 6 mice were tested per group and per time point. The IL-18 variants were administered via a single intravenous injection. The mice were divided into four dose groups: 0.5 mg / kg, 0.1 mg / kg, 0.02 mg / kg, 0.004 mg / kg; and four time point groups: 5 min, 6 h, 24 h, 48 h. In a separate experiment, PD and PD were measured according to the method provided for C57BL / 6 mice, but healthy mice were replaced with tumor model mice (e.g., mice with MC-38 tumor cell xenografts).

[0398] The immune-related PD effect was determined by analyzing the cytokine levels in plasma. The following plasma cytokines were measured: IFNγ, CXCL9, CXCL10, GM-CSF, IL-1a, FasL and IL-18BP. The activation state of leukocytes was determined by monitoring the following surface markers: ICOS, PD-1, CD25, CD69 and Fas. Bioanalysis was performed by detecting the total amount of IL-18 variants (free and IL-18BP complexed). Corning high binding half-area plates (Fisher Scientific, Reinach, Switzerland) were coated overnight with 25 μl of 2 μg / ml anti-IL18 monoclonal antibody (MBL, cat#D043-3, clone 25-2G) in PBS at 4°C. The plate was then washed four times with 100 μl PBS-0.02% Tween20. The plate surface was blocked with 25 μl PBS-0.02% Tween20-1% BSA at 37°C for 1 h. The plate was then washed four times with 100 μl PBS-0.02% Tween20. 25 microliters of IL-18 variants (or mouse plasma) were added to PBS-0.02% Tween20-0.1% BSA in 8-fold serial dilutions (from 50 nM down to 0.02 nM) and incubated at 37°C for 2 h. The plate was then washed four times with 100 μl PBS-0.02% Tween20 and 25 μl of 2 μg / ml biotinylated anti-IL18 monoclonal antibody (MBL, cat# D045-6, clone 159-12B) in PBS. The plate was incubated at 37°C for 2 h and then washed 4 times with 100 μl PBS-0.02% Tween20. 25 microlitres of streptavidin-horseradish peroxidase (#RABHRP3, Merck, Buchs, Switzerland) diluted 1:500 in PBS-0.02% Tween20-0.1% BSA were added to each well and incubated at room temperature for 30 min. The plate was then washed four times with 100 μl PBS-0.02% Tween20. 50 microlitres of TMB substrate reagent (#CL07, Merck, Buchs, Switzerland) were added to each well and incubated at 37°C for 5 min. After 5 min at 37°C, the horseradish peroxidase reaction was terminated by adding 0.5M H2SO4 stop solution of 50 μl / well. The ELISA signal at 450 nm was then measured on the EnSpire plate reader of Perkin Elmer (Schwerzenbach, Switzerland).

[0399] Due to the presence of the artificial terminal moiety, PK and PD in healthy mice showed little IL-18-related activity after administration of the Act-IL-18 peptide, but slight effects may be measured due to the presence of endogenous proteases that may cleave the artificial terminal moiety at a low background rate. The distribution of active IL-18 and IL-18 activity was not specific to any tissue.

[0400] In contrast, tumor model mice that received the Act-IL-18 peptide with an artificial terminal portion that was preferentially cleaved by tumor-associated proteases exhibited high local levels of the active form of IL-18 and signs of IL-18 activity in and around the tumor microenvironment, but very little in and immediately adjacent to the tumor.

[0401] Example 13 - PBMC stimulation assay

[0402] The ability of IL-18 variants to stimulate peripheral blood mononuclear cells (PBMCs) was assessed according to the following protocol.

[0403] Isolation of lymphocytes: Blood from buffy coats of healthy volunteers was diluted with an equal volume of PBS and slowly poured on top of a SepMate tube pre-filled with 15 mL of Histopaque-1077. The tube was centrifuged at 1200 g for 10 minutes, the top layer was collected and washed three times with PBS containing 2% fetal bovine serum. PBMCs were counted and cryopreserved in aliquots of 20 × 106 cells.

[0404] Cryopreserved PBMCs were thawed and stimulated with a gradient of human IL-18 variants ranging from 0.2 pM to 1 μM in RPMI containing 10% fetal bovine serum.

[0405] After 24 h stimulation, cytokine production was measured on a multicolor flow cytometer by Legendplex (Biolegend #740930). Release in the culture supernatant was calculated based on variable slope and four-parameter analysis using GraphPad PRISM software. half maximal effective concentration (EC50).

[0406] After 72 h stimulation, surface expression of FcγRIII (mouse IgG1 clone 3G8) on NK cells was measured by flow cytometry.

[0407] The Act-IL-18 variants of the present disclosure are active and able to induce IFNγ secretion in vitro after cleavage of the artificial terminal moiety, but are shown to have reduced or no ability to induce IFNγ in the absence of cleavage.

[0408] Although the present disclosure and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the disclosure as defined by the appended claims.

Claims

1. An activatable interleukin 18 (Act-IL-18) polypeptide, the Act-IL-18 polypeptide comprising: an artificial terminal portion linked to an interleukin 18 (IL-18) polypeptide, wherein the artificial end portion comprises a specific cleavage site, and Wherein cleavage at the specific cleavage site converts the Act-IL-18 into an active form of the IL-18 polypeptide.

2. The Act-IL-18 polypeptide of claim 1, wherein when the artificial end portion is intact, the Act-IL-18 is inactive.

3. The Act-IL-18 polypeptide of claim 1 or 2, wherein the specific cleavage site is preferentially cleaved at or near a target tissue in a subject.

4. The Act-IL-18 polypeptide of any one of claims 1 to 3, wherein the specific cleavage site is preferentially cleaved in or near a tumor microenvironment.

5. The Act-IL-18 polypeptide of any one of claims 1 to 4, wherein the specific cleavage site is specifically cleaved by a protease.

6. The Act-IL-18 polypeptide of claim 5, wherein the protease is present at a higher concentration and / or exhibits a higher proteolytic activity in the tumor microenvironment relative to non-tumor tissues.

7. The Act-IL-18 polypeptide of claim 5 or 6, wherein the protease is selected from the group consisting of kallikrein, thrombin, chymase, carboxypeptidase A, elastase, proteinase 3 (PR-3), granzyme M, urokinase plasminogen activator (uPA), calpain, matrix metalloproteinase (MMP), a disintegrin and metalloproteinase (ADAM), fibroblast activation protein alpha (FAP), matriptase, plasminogen activator, cathepsin, caspase, tryptase, and tumor cell surface protease.

8. The Act-IL-18 polypeptide of any one of claims 5-7, wherein the artificial end portion comprises a peptide having a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to a peptide sequence listed in Table 2A.

9. The Act-IL-18 polypeptide of any one of claims 5-7, wherein the artificial end portion comprises a peptide having a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to a peptide sequence listed in Table 2B.

10. The Act-IL-18 polypeptide of any one of claims 1-4, wherein the specific cleavage site is a redox-sensitive cleavage site.

11. The Act-IL-18 polypeptide of claim 9, wherein the redox-sensitive cleavage site is preferentially cleaved in a reducing environment.

12. The Act-IL-18 polypeptide of any one of claims 1-4, wherein the specific cleavage site is a pH-sensitive cleavage site.

13. The Act-IL-18 polypeptide of claim 12, wherein the pH-sensitive cleavage site is preferentially cleaved at a pH below 7.3, below 7.2, below 7.1, or below 7.

0.

14. The Act-IL-18 polypeptide of any one of claims 1-13, wherein the cleavage removes the entire artificial terminal portion from the IL-18 polypeptide.

15. The Act-IL-18 polypeptide of any one of claims 1-13, wherein the cleavage results in a portion of the artificial moiety remaining attached to the IL-18 polypeptide.

16. The Act-IL-18 polypeptide of any one of claims 1-15, wherein the artificial end portion comprises a peptide.

17. The Act-IL-18 polypeptide of claim 16, wherein cleavage of the artificial terminal moiety at the specific cleavage site leaves no amino acid residues of the peptide attached to the IL-18 polypeptide.

18. The Act-IL-18 polypeptide of claim 16, wherein cleavage of the artificial terminal moiety at the specific cleavage site leaves at least one amino acid residue of the peptide attached to the IL-18 polypeptide.

19. The Act-IL-18 polypeptide of claim 16 or 18, wherein cleavage of the artificial end portion at the specific cleavage site leaves 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid residues of the peptide attached to the IL-18 polypeptide.

20. The Act-IL-18 polypeptide of any one of claims 16-19, wherein the peptide comprises multiple specific cleavage sites.

21. The Act-IL-18 polypeptide of any one of claims 16-20, wherein the peptide comprises 2, 3 or 4 specific cleavage sites.

22. The Act-IL-18 polypeptide of any one of claims 1-21, wherein the artificial terminal moiety is attached to the N-terminus or the C-terminus of the IL-18 polypeptide.

23. The Act-IL-18 polypeptide of claim 22, wherein the artificial terminal moiety is attached to the N-terminus of the IL-18 polypeptide.

24. The Act-IL-18 polypeptide of claim 23, wherein the artificial end portion comprises a blocking moiety.

25. The Act-IL-18 polypeptide of claim 24, wherein the blocking moiety is positioned such that cleavage at the specific cleavage site releases the blocking moiety from the Act-IL-18 polypeptide.

26. The Act-IL-18 polypeptide of claim 24 or 25, wherein the blocking moiety comprises an IL-18 propeptide or a portion thereof, or a variant thereof.

27. The Act-IL-18 polypeptide of claim 26, wherein the IL-18 propeptide is a human IL-18 propeptide or a variant thereof.

28. The Act-IL-18 polypeptide of claim 26, wherein the IL-18 propeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence shown in SEQ ID NO:

89.

29. The Act-IL-18 polypeptide of any one of claims 24 to 28, wherein the artificial terminal moiety comprises a connecting peptide between the specific cleavage site and the blocking moiety.

30. The Act-IL-18 polypeptide of claim 22, wherein the artificial terminal moiety is attached to the C-terminus of the IL-18 polypeptide.

31. The Act-IL-18 polypeptide of claim 30, wherein the artificial end portion comprises a blocking moiety.

32. The Act-IL-18 polypeptide of claim 31, wherein the blocking moiety is positioned such that cleavage at the specific cleavage site releases the blocking moiety from the Act-IL-18 polypeptide.

33. The Act-IL-18 polypeptide of claim 31 or 32, wherein the blocking moiety comprises a domain of an IL-18 receptor subunit or a portion thereof, or a derivative thereof.

34. The Act-IL-18 polypeptide of claim 33, wherein the domain of the IL-18 receptor subunit comprises the D3 domain of the IL-18 receptor alpha subunit, or a variant thereof.

35. The Act-IL-18 polypeptide of any one of claims 33 or 34, wherein the blocking moiety comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence shown in SEQ ID NO:

93.

36. The Act-IL-18 polypeptide of any one of claims 31 to 35, wherein the artificial end portion comprises a connecting peptide between the specific cleavage site and the blocking portion.

37. The Act-IL-18 polypeptide of any one of claims 1-36, wherein the active form of the IL-18 polypeptide exhibits reduced binding to IL-18 binding protein (IL-18BP) compared to WT IL-18.

38. The Act-IL-18 polypeptide of any one of claims 1-37, wherein the active form of the IL-18 polypeptide exhibits enhanced ability to bind to or activate IL-18R.

39. The Act-IL-18 polypeptide of any one of claims 1-37, wherein the active form of the IL-18 polypeptide exhibits up to a 100-fold reduction in the ability to bind to or activate IL-18R relative to WT IL-18.

40. The Act-IL-18 polypeptide of any one of claims 1-39, wherein the IL-18 polypeptide comprises one or more modifications to the sequence shown in SEQ ID NO:

1.

41. The Act-IL-18 polypeptide of claim 40, wherein the IL-18 polypeptide comprises an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the sequence shown in SEQ ID NO:

1.

42. The Act-IL-18 polypeptide of claim 40 or 41, wherein the IL-18 polypeptide comprises at least one substitution at the following residues: Y1, F2, E6, C38, K53, D54, S55, T63, C76, E85, M86, T95, D98 or C127, or any combination thereof.

43. The Act-IL-18 polypeptide of any one of claims 40-42, wherein the IL-18 polypeptide comprises Y01G, F02A, E06K, V11I, C38S, C38A, K53A, D54A, S55A, T63A, C76S, C76A, E85C, M86C, T95C, D98C, C127S or C127A amino acid substitutions, or any combination thereof.

44. The Act-IL-18 polypeptide of any one of claims 40-43, wherein the IL-18 polypeptide comprises E06K and K53A amino acid substitutions.

45. The Act-IL-18 polypeptide of any one of claims 40-44, wherein the IL-18 polypeptide comprises a T63A amino acid substitution.

46. ​​The Act-IL-18 polypeptide of any one of claims 40-45, wherein the IL-18 polypeptide comprises a V11I amino acid substitution.

47. The Act-IL-18 polypeptide of any one of claims 40-46, wherein the IL-18 polypeptide comprises substitutions at 1, 2, 3 or 4 residues selected from C38, C76, C98 and C127.

48. The Act IL-18 polypeptide of claim 40, wherein the IL-18 polypeptide comprises the amino acid sequence shown in any one of SEQ ID Nos: 2-67.

49. The Act IL-18 polypeptide of claim 40, wherein the IL-18 polypeptide comprises the amino acid sequence shown in SEQ ID NO:

30.

50. The Act-IL-18 polypeptide of claim 40, wherein the IL-18 polypeptide comprises the amino acid sequence shown in any one of SEQ ID NOs: 79-83.

51. The Act IL-18 polypeptide of any one of claims 1-50, wherein the Act IL-18 polypeptide exhibits a half maximal effective concentration (EC 50) of IL-18 receptor signaling activity that is at least 1,000-fold higher, 2,000-fold higher, 5,000-fold higher, 10,000-fold higher, 15,000-fold higher, or 20,000-fold higher than an activated form of the IL-18 polypeptide. 50 ).

52. The Act IL-18 polypeptide of any one of claims 1-50, wherein the Act IL-18 polypeptide exhibits a half-maximal effective concentration (EC 50) of IL-18 receptor signaling activity that is about 10-fold to about 100-fold higher than the activated form of the IL-18 polypeptide. 50 ).

53. The Act-IL-18 polypeptide of any one of claims 1-52, wherein the activated form of the IL-18 polypeptide exhibits a half maximal effective concentration (EC 50) of IL-18 receptor signaling activity that is within about 10-fold of that of the IL-18 polypeptide. 50 ).

54. The Act-IL-18 polypeptide of any one of claims 1-53, wherein the Act-IL-18 polypeptide exhibits a half-maximal effective concentration (EC 50) of IL-18 receptor signaling activity that is at least 1000-fold greater than that of WT IL-18. 50 ).

55. The Act-IL-18 polypeptide of any one of claims 1-54, wherein the Act-IL-18 polypeptide exhibits a half-maximal effective concentration (EC 500) of IL-18 receptor signaling activity that is at least 10-fold greater than that of WT IL-18. 50 ).

56. The Act-IL-18 polypeptide of any one of claims 1-55, wherein the IL-18 polypeptide is synthetic.

57. The Act-IL-18 polypeptide of any one of claims 1-56, comprising a polymer linked to a residue of the IL-18 polypeptide.

58. A pharmaceutical composition comprising: a) the Act-IL-18 polypeptide of any one of claims 1-57; and b) a pharmaceutically acceptable carrier or excipient.

59. A method of treating cancer in a subject in need thereof, the method comprising: A pharmaceutically effective amount of the Act-IL-18 polypeptide of any one of claims 1 to 57 or the pharmaceutical composition of claim 58 is administered to the subject.

60. The method of claim 59, wherein the cancer is a solid cancer.

61. The method of claim 60, wherein the solid cancer is adrenal cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, carcinoid, cervical cancer, colorectal cancer, esophageal cancer, eye cancer, gallbladder cancer, gastrointestinal stromal tumors, germ cell cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, neuroendocrine cancer, oral cancer, oropharyngeal cancer, ovarian cancer, pancreatic cancer, pediatric cancer, penile cancer, pituitary cancer, prostate cancer, skin cancer, soft tissue cancer, spinal cord cancer, stomach cancer, testicular cancer, thymus cancer, thyroid cancer, ureter cancer, uterine cancer, vaginal cancer, or vulvar cancer.

62. The method of claim 60, wherein the solid cancer is metastatic renal cell carcinoma or melanoma.

63. The method of claim 60, wherein the solid cancer is a carcinoma or a sarcoma.

64. The method of claim 59, wherein the cancer is a hematological cancer.

65. The method of claim 64, wherein the hematological cancer is leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, AIDS-related lymphoma, multiple myeloma, plasmacytoma, post-transplant lymphoproliferative disorder, or Waldenstrom's macroglobulinemia.

66. The method of any one of claims 59-65, further comprising reconstituting a lyophilized form of the Act-IL-18 polypeptide or the pharmaceutical composition.